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Abstract
The effect of cancer therapy could be greatly improved by encapsulating existing
drugs into nanoparticles. Nanoparticles can facilitate delivery of hydrophobic
drugs with poor solubility in water, and allow you to target cancer cells specifi-
cally either through passive targeting, active targeting or triggered drug delivery.
This thesis explores the cellular uptake and intracellular degradation of a novel,
multimodal polymeric nanoparticle developed at SINTEF Materials and Chem-
istry.
Two types of nanoparticles were evaluated for drug delivery purposes. Flu-
orescence lifetime imaging and analysis of emission spectra were used to assess
the intracellular degradation, confocal laser scanning microscopy and flow cy-
tometry were used to characterized the uptake. It was found that the poly(butyl
cyanoacrylate) particle has degraded considerably after 24 hours intracellularly
and is taken up through clathrin-mediated endocytosis. It was found that the cel-
lular uptake was highly dependent on cell confluency and maturation. The poly
(octyl cyanoacrylate) nanoparticle was not found to degrade readily within the
first week of cell contact and is therefore less promising for drug delivery purposes.
However, it was found that after 3 hours the particle had at least 3-fold higher
uptake in prostate cancer cells than the poly(butyl cyanoacrylate) particle and
that both clathrin- and caveolin-mediated uptake was important mechanisms in
this uptake. This particle might be useful either for slow delivery or imaging. It
was found indications that the nanoparticles escape the lysosomes and degrades
in cytosol which is beneficial for drug delivery.
vi
Sammendrag
Dagens kreftbehandling kan forbedres betydelig ved a˚ bruke nanopartikler til
a˚ frakte kreftmedisinen gjennom kroppen og levere den i tumor. Nanopartik-
ler gjør det mulig a˚ utnytte cytotoksiske stoffer som normalt er for hydrofobe
eller ustabile til a˚ brukes i fri form. I tillegg kan nanopartikler gjøre det mulig
a˚ rette behandlingen mer spesifikt mot kreftceller ved passiv/aktiv m˚alsøking,
eller ved hjelp av ekstern stimuli som for eksempel ultralyd. Denne masteropp-
gaven beskriver cellulært opptak og intracellulær nedbrytning av en nye type
multimodale polymernanopartikler utviklet ved SINTEF Materialer of Kjemi.
Et nytt, svært hydrofobt fluoriserende fargestoff har blitt utviklet for a˚ kunne
merke partiklen utene at fargestoffet lekker ut. I denne oppgaven er det vist at
dette fargestoffet ogs˚a kan brukes til a˚ m˚ale nedbrytningen av partiklene ved a˚
se p˚a levetiden til den eksiterte tilstanden i fluoroforen.
To partikkeltyper har blitt vurdert for bruk til medisinlevering basert p˚a ned-
brytning. Det ble funnet at poly (butyl cyanoakrylat) partikkelen brytes ned i et
tempo som er godt egnet for levering av kreftmedisin. Disse partiklene ble tatt
opp av prostatakreftceller ved clathrinmediert endocytose. Opptaket var sterkt
avhengi av celletetthet og modenhet, det vil si antall dager etter at cellene ble
s˚add ut. Partikler av poly (oktyl cyanoakrylat) ble ikke brutt ned i betydelig
grad i løpet av den første uken i kontakt med celler. Dette er for tregt for me-
disinlevereng, men kan være ideelt for avbildingsapplikasjoner. Etter 3 timer
var tre ganger mer av disse partiklene tatt opp enn av poly (butyl cyanoakry-
lat) partiklene, trolig fordi ogs˚a caveolinmediert endocytose bidro til opptaket.
Fluoresenslevetid og analyse av emisjonsspekter ble brukt for a˚ kartlegge ned-
brytningen av partiklene. Konfokalmikroskop og flow cytometer ble brukt for a˚
kartlegge opptaket. Det ble vist at fluoresenslevetid med fargestoffet NR668 er
en svært følsom metode for a˚ m˚ale intracellulær nedbrytning.
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Chapter 1
Introduction
Treating cancer is one of the main challenges in modern healthcare, cancer being
one of the most deadly diseases in the developed world. The disease arises from
cells that through mutations acquire the ability to proliferate uncontrolled and
avoid systematic and intracellular control systems. Existing therapy is often
insufficient and suffers from adverse side effects.
Nanotechnology has been introduced as the toolbox necessary to create novel
platforms both for drug delivery and for cancer diagnostics. A wide array of
systems have been proposed, but few have made it through the trial stage. The
concept suggested is often to bind or encapsulate an existing drug to a nano
sized carrier that will selectively deliver the drug at the tumor site. This is an
intriguing thought that has proven very challenging. These systems would in
principle both increase the amount of drug delivered to the tumor and lower the
dose released systemically. Nano sized particles are known to target solid tumors
through the enhanced permeability and retention (EPR) effect[1][2]. Exploiting
the EPR effect is known as passive targeting. Systems using active targeting
(selectively binding surface molecules)[3] and triggered drug delivery[4] have also
been proposed.
A novel drug delivery platform based on biodegradable polymeric nanopar-
ticles (NPs) has been designed at SINTEF Materials and Chemistry (data not
published). The NPs are made through polymerization of poly(alkyl cyanoacry-
late)(PACA) in an one-step miniemulsion synthesis. The particles can be loaded
with drugs and imaging agents, and the surface can be functionalized with tar-
geting proteins and poly ethylene glycol (PEG). These NPs can also be used to
stabilize microbubbles, this system has been demonstrated for triggered drug de-
livery and imaging using ultrasound [5]. Drug delivery based on PACA NPs is
considered very promising due to the biocompatibility and tunable biodegrada-
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tion of the material and several systems based on these particles are under clinical
development for cancer treatment[6].
In order to further develop this platform, it is important to throughly under-
stand how these particles interact with cells. This includes the rate and pathway
of cellular uptake, and the intracellular fate of the NPs. To maximize the ef-
fect of the encapsulated drug, it should be delivered at its target by the NP,
this is in most cases intracellularly. Characterizing that properties that dictate
the uptake and if receptors are involved would help in further development of
the NPs However, uptake through endocytosis often leads to lysosomal degrada-
tion and inactivation of the drug. The particles produced at SINTEF Materials
and Chemistry has a tunable degradation depending on the choice of monomer.
Detailed knowledge of the rate and location of the intracellular delivery of the
drug is crucial in order to accurately characterize the drug delivery platform. In
this study, two PACA NPs with different rate of degradation[7] was used. These
particles are made from either poly(octyl cyanoacrylate) (POCA) or poly(butyl
cyanoacrylate)(PBCA).
1.1 Project motivation
The purpose of this master thesis was to evaluate the uptake and intracellular fate
of PACA NPs in human cancer cells in vitro. If the NPs were internalized by the
cells, the intracellular degradation or clearance would be assessed. An important
goal of this project was to establish a method for evaluating the intracellular
degradation of the NPs and this was done using imaging techniques such as
fluorescence lifetime imaging (FLIM) and spectral analysis. The overall goal was
to evaluate the potential for degradation dependent drug delivery of the two
different NPs.
Chapter 2
Theory
This thesis is a continuation of the 5th year project thesis written fall 2013 [8] and
some of the theory, especially the section on the properties of the NPs (section
2.3) has been adapted from that thesis.
2.1 Cancer
Cancer is one of the main health problems in the world, according to the World
Health Organization accounting for around 13% of deaths[9]. According to the
Cancer registry of Norway, every third norwegian will be diagnosed with cancer
before turning 75[10]. In 2011, we had 30000 new cases of cancer in Norway.
Cancer is a collection of diseases based on uncontrolled growth and lack of
regulation of our own cells. The disease can be of different nature and can have
multiple causes[11]. Cancer typically starts as a single cell malfunctioning due to
mutations in its DNA. The change could either up regulate a cancer promoting
gene (oncogene), or down regulate a tumor suppressing gene. Either way, the
mutation leads to uncontrolled duplications of this cell. The evolution of the
disease typically goes through invasion of surrounding tissue and metastasis to
near and distant sites. These traits distinguish cancer from benign growths.
There are many exceptions to these steps, exemplified by cancers circulating in
the blood or in the lymphatic system such as leukemia and lymphoma. There is a
wide array of genes that through mutations can promote cancer, cancer cells are
therefore both very similar to our healthy cells yet extremely diverse making them
hard both for the immune system to identify and to medicate without also causing
extensive damage to the patient. There are intense research in the field and
according to The Association of the Pharmaceutical Industry in Norway (LMI),
the survival chances of cancer patients have doubled during the last 50 years.
3
4 CHAPTER 2. THEORY
Still, chemotherapy, radiotherapy and surgery which are the current treatment
options all have drawbacks in terms of efficiency and side effects. New knowledge
of genes promoting and suppressing cancer (oncogenes and tumor suppressor
genes) has paved way for the development of better, more tailored chemotherapy.
However, this method still suffers from systemic distribution after intravenous
delivery which results in the necessity of high drug doses resulting in side effects.
Increasing the specificity of chemotherapy has been a holy grail in cancer medicine
for decades[12].
2.1.1 Cancer treatments
Many cancer types are greatly affected by lifestyle and environment. The most
effective way to fight cancer is by prevention. All other treatments today have
different severe side effects and often yield limited results. The classic methods of
treatment can be divided into radiotherapy, chemotherapy and surgery, these are
often used in combination. While surgery and radiotherapy are options for solid,
non-metastasized tumors, chemotherapy is the most common option for devel-
oped, late stage cancer. Surgery is the best option for superficial cancers, while
radiotherapy is often used if surgery is difficult for example in brain tumors[11].
Radiotherapy is based on radiating the tumor cells from many directions to cre-
ate a high dose of exposure only at the tumor. The radiation will then create
fractures in the DNA strands of these cells, inducing chromosomal aberration and
mitotic death[13]. Radiation is carcinogenic and reoccurring cancers are common,
making it a non-ideal therapy[11][14].
Chemotherapy is the use of cytotoxic or cytostatic drugs that kill malignant
cells or stop them from proliferating. They often target steps in the cell cycle
making them effective towards all proliferating cells. In addition to malignant
cells, this involves cells in the immune system or blood cells and stem cells pro-
ducing hair in the hair follicles. Also, targeting dividing cells makes chemother-
apy work poorly on tumor stem cells or quiescent G0 cells[15]. While traditional
chemotherapy generally targets all dividing cells, intense work is directed towards
more intelligent chemotherapy targeting the signaling pathway being up or down
regulated in the specific case of cancer[16].
2.1.2 The biology of a tumor and therapeutic barriers
One main attribute of a tumor is the fact that the cells are proliferating. This
process has a high demand for oxygen and nutrients. Up to a size of 2mm3, the tu-
mor is being fed by passive diffusion[17]. Larger tumors will suffer hypoxia unless
blood vessels are formed, and at this point, successful tumors start angiogenesis,
or blood vessel formation[18]. Typical for angiogenesis in tumors is that is occurs
rapidly and unorganized. This creates areas of poor vascularization resulting in
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local necrosis, and areas of dense vascularization[17]. Another effect of this rapid
angiogenesis is that created vessels typically are branched, short-circuited and
of uneven diameter, with poorly constructed leaky walls. The size of the gaps
between the endothelial cells are reported to be from 200nm to 1.2µm depending
on tumor type[19]. However, it is documented that the vascularization and leaki-
ness of the vessel is very heterogeneous within a tumor[20][21]. The gap between
endothelial cells in healthy vessels is approximately 5− 10nm. Leaky vesicles in
tumors are a possibility for passive targeting by exploiting the EPR-effect (en-
hanced permeability and retention)[22]. The leaky vesicles lead to the enhanced
permeability, the retention effect is caused by a poorly developed or non-existing
lymphatic system in the tumor. While the lymphatic system normally would
remove NPs from the extracellular compartment, NPs can often remain in the
tumor[23]. While the leakiness of the new vesicles around the tumor can be used
to target tumors, it can also present a challenge. A natural effect of an immature
vesicle system is low blood flow making it hard to get a sufficient concentration
of drugs and NPs. It is seen that areas of low blood flow are hard to treat and
often survive therapies[24].
One significant effect of the late and poor vascularization is that tumors evolve
under a lack of oxygen and nutrients. This forces the tumor cells to perform
anaerobe metabolism. It is unclear what mechanisms lead tumors into perform-
ing glycolysis, but it is well documented that most tumors use glycolysis also
when oxygen is sufficiently provided (normoxia)[18]. Glycolysis is ineffective and
produces only two ATP while complete oxidation results in 32 ATP produced[25].
Therefore, tumors normally have a very high consumption of nutrients, which can
be exploited both for imaging and targeted therapy. Glycolysis results in the pro-
duction of lactic acid which gives lower pH in tumors compared to healthy tissue.
While the pH of blood is held around 7.4, tumors have been reported to have pH
values down to 5.6[26].
While angiogenesis, leaky vesicles and acidic environments are properties that
can be exploited for targeted delivery, there are also properties of tumors that
make drug delivery challenging. Due to the poor vascularization, there will be tu-
mor cells surviving on marginal conditions, far from any blood vessels. These cells
are hard to reach with classical drug delivery and require new methods. Tumors
also typically have a higher interstitial pressure than the surrounding tissue[27].
The interstitial pressure in a tumor is highest at its center, and decreases towards
the periphery[28]. This high pressure is a result of the retention caused by the
lack of a lymphatic system in the tumor. This phenomenon reduces the convec-
tion of molecules towards the center of the tumor because of the counter acting
convection created by the interstitial pressure and makes it difficult to deliver
drugs to this central area.
6 CHAPTER 2. THEORY
Non-tumor related obstacles
Getting a drug to the tumor intact, functioning and at a sufficient concentration
is very challenging. Therapeutic agents are typically given intravenously, and
once in the blood many processes and a series of obstacles will be presented to
make sure the drug/NP is removed from the circulatory system[11]. The innate
immune system consists amongst others of complement protein that will bind
anything foreign and of a notable size. Protein coverage called opsonization leads
to phagocytosis by monocytes and macrophages. This is called the reticuloen-
dothelial system (RES)[29].
The extra cellular matrix (ECM) also presents a challenge for drug transport.
ECM is a combination of networks of fibrous proteins such as collagen and elastin
and highly viscous fluids. Although ECM is often degraded in a tumor, ECM
reduces the flow of drugs once the drug has left the circulatory system. Another
limiting obstacle is cell internalization. Most drugs must be delivered inside
the cell in order to function. This often means going through endocytosis (cell-
eating), where the drug is encapsulated in early endosome, late endosome and
finally lysosome. In this process, the drug faces pH ranging from 7.4 and down
to 5[25][29].
2.1.3 Cancer targeting and nanoparticles
The drugs being used in chemotherapy are toxic to many healthy cells. By finding
better ways of targeting the tumor cells one could limit the adverse effects by both
interacting less with healthy cells and lowering the dose due to increased concen-
tration around the tumor[30]. In order to find ways to target these cells, detailed
knowledge about the environment in and around a tumor is a prerequisite.
Nanotechnology could be the toolbox necessary to overcome limitations of
current chemotherapy. While chemotherapeutic agents can not be altered without
also changing the cytotoxic function of the molecule, NPs are promising platforms
for delivering these toxic agents to the cells in the tumor[31]. NPs can be loaded
with conventional chemotheraputics and increase the load delivered at the wanted
location. Besides targeting, nanocarriers are also a way of delivering drugs that
have properties that have made them unsuitable so far, such as adverse side effects
and poor solvability in water/hydrophobicity. Targeting of cancer cells is a huge
field of research, and multiple strategies and platforms are being developed. The
strategies can be divided into three categories; passive targeting, active targeting
and triggered drug delivery. These three options will be discussed in the following
section.
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Passive targeting
Passive targeting of NPs to cancer tissue relies on the EPR effect[32]. NPs that
circulate in the vasculature will not be able to penetrate through the endothelial
layer of healthy tissue and will therefore remain in circulation until removed by
the RES-system. The enhanced permeability often present in cancers will allow
the NPs to leave the bloodstream and the lack of functional lymphatic system
will allow the particles to accumulate in the tissue[23]. The potential of passive
targeting depends on the vascularity and leakiness of the veins in the tumor, but
the process has low efficiency, and long-circulating NPs are necessary[33]. Drug
delivery is also normally limited by very slow diffusion, especially of bigger NPs
(>100nm), in the tumor tissue, but is has recently been shown that by increasing
the amount of poly ethylene glycol (PEG), particles above 100nm can diffuse
effectively through brain tissue and this result is likely valid for other tissues as
well[34]. Covering a surface with PEG (pegylation) is a method to decrease the
hydrophobicity and increase the biocompatibility of the particle that is further
described in section 2.3.2.
Active targeting
In active targeting, the particles are surface functionalized with molecules selec-
tively targeting receptors on the target cells and tissue. Targeting nanocarriers
that are approved or in phase one trials have typically utilized antibodies, trans-
ferrin or interleukin 2 (Il-2) for targeting[35]. Transferrin receptors are expressed
by many cancer types while Il-2 receptors are highly expressed on malignant
T-cells (T-cell leukemia)[36]. Particles have also been targeted to avoid the P-
glycoprotein (P-gp) eﬄux pump upregulated in many cancers and often respon-
sible for multidrug resistance[37].
Triggered drug delivery
Triggered drug delivery is a targeting tactic where external stimuli is used to
direct the NP or to release the drug. This can be changes in local environment
such as temperature, pH or salt concentration[38][4], or external sources such as
light, heating and ultrasound[39][40]. Ultrasound is also being developed for drug
delivery in combination with microbubbles[41].
2.2 Nanoparticles and medicine
Intense research is currently being aimed at creating NPs for biomedical applica-
tions such as drug delivery, biosensing and as contrast agents for imaging[42]. The
concept is to create a particle that can be functionalized to target specific cells or
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organs. The drug or contrast agent can either be attached to the surface of the
particle, encapsulated by a shell or mixed into the particle material. Common
to all potential systems are some necessary features. The particle must be bio-
compatible. This means that it should not be toxic nor should it be taken up by
phagocytes in the immune system. Biocompatible also means that the particle is
either degraded in the body or removed by the kidneys to avoid accumulation[43].
Nanosized objects have some intrinsic characteristics for biomedical applica-
tions. NPs have a high surface to volume ratio making their properties highly
dependent on their surface. The properties of a NP can be changed significantly
based only on the surface chemistry. There is a wide range of developed particles,
in terms of material, size and shape, where many have all ready been approved
either for phase one trials or for clinical use[44]. NPs are also able to carry drugs.
Drugs are small molecules that are distributed in the blood and are typically
taken up non-specifically by cells or simply diffuse through cell membranes. This
makes it impossible to target cells or organs. NPs on the other hand are small
enough to flow through small capillaries and leak through the capillary walls in
tumors, but are too large to escape healthy blood vessels or diffuse through cell
layers. Diffusion through cell ECM is limited and highly dependent on properties
such as charge and pegylation[34]. Also, they require active transport to be taken
up by cells[45][46]. At least in theory, this makes it possible to design the particle
to interact only with specific cells. Practically, this is still difficult but is being
studied intensively.
NPs generally have properties controlled by their size and shape, biolog-
ical properties are also highly dependent on surface chemistry and targeting
groups[47]. Most proposed and developed NPs, shape and structural options
and some examples of possible surface chemistries and targeting groups are sum-
marized in figure 2.1. The particles used in this study falls under the category
polymeric NPs and will be described in detail in the next section.
2.3 Poly (alkyl cyanoacrylate) nanoparticles
The particles used in this project are polymer NPs made from polymerization
of alkyl cyanoacrylate giving poly(alkyl cyanoacrylate)(PACA). PACA was ini-
tially developed for use as a surgical glue due to its biocompatibility and quick
polymerization[6]. The material is now intensively studied and developed to be
used for therapy and diagnostics as a nanocarrier of drugs or contrast agents
for imaging. Two different subgroups have been studied, poly (butyl cyanoacry-
late)(PBCA) and poly(octyl cyanoacrylate) (POCA). The most widely used ma-
terial is PBCA, but also POCA is being studied and has the advantage of slower
degradation and lower toxicity[48]. PACA NPs are typically produced through a
miniemulsion process giving a tunable size often in the 100-300nm region[49][50].
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Figure 2.1: Illustration summarizing different NPs and characteristics important
for their properties. Adapted from [47].
The miniemulsion process also makes it possible to mix in other hydrophobic
molecules and is normally stabilized by a surfactant that organizes at the par-
ticle surface. Through choosing surface molecules and load, PACA NPs can be
produced with different properties dependent on the application. Often though,
the surface is covered by PEG (poly ethylenglycol) to sterically stabilize the par-
ticle and improve the biocompatibility[51]. Figure 2.2 is an illustration of the
PACA NPs made at SINTEF with its potential loads and surface.
2.3.1 Emulsions and nanoemulsions
The NPs are produced through an emulsion and nanoemulsion process. Although
an emulsion can be produced from almost any two immiscible liquids, the two
liquids are most often oil and water. A pure mixture of oil and water will separate
into two distinct phases that can easily be separated. An emulsion is produced
by adding an emulsifying agent, also known as a surfactant. A surfactant is
a molecule that spontaneously arranges itself at the oil-water interphase. This
happens because the surfactant has two distinct regions; a polar part that is
soluble in water, and a non-polar part that is soluble in oil. The surfactants used
on the particles are described in section 2.3.2.
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Figure 2.2: Illustration of the PACA NPs used in this project. Illustration
adapted from a presentation by Yrr Mørch.
With the surfactant in place, the oil-water system may be mixed into an
emulsion where one medium is dispersed (the inner phase) in the other (the
continuous phase), with the surfactant at the interface. This system is only
kinetically stable, this means that with enough time the system will separate
back into two distinct phases. BCA and OCA, the monomers used in the NPs
are hydrophobic, and are mixed in a neutral oil, water and a surfactant to create
an oil in water emulsion. The hydrophobic oil is used as a co-stabilizer to avoid
Oswald ripening, a destabilizing mechanism where large particles grow on expense
of smaller ones[52]. Other molecules to be included in the NP must be mixed into
the oil phase at this step. By radiating the solution with high power ultrasound,
the droplet size can be reduce from micrometer to the nanometer regime and
become a nanoemulsion. The nanoemulsion shares most of its properties with
the standard emulsion, but while the emulsion contains polydisperse droplets
and appear cloudy, the nanoemulsion contains droplets in the nanometer range
and often appears translucent[53].
2.3.2 Polymerization and pegylation
While the motivations and effects of adding PEG to a particle surface are explored
in section 2.3.3, the method for binding PEG to the surface is included here
because it is a part of the polymerization step.
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BCA (figure 2.3) and OCA (figure 2.4) are highly reactive and will generally
polymerize easily. The polymerization happens through anionic polymerization.
Anionic polymerization starts when a nucleophile (such as an amine or a hydrox-
ide ion) carrying a free electron pair reacts with the BCA or OCA monomer.
To avoid premature polymerization, the emulsion is prepared under acidic con-
ditions. The excess of hydrogen ions in acidic solutions prevents formation of
negative ions. The polymerization reaction of PBCA is illustrated and briefly
explained in figure 2.5.
Figure 2.3: The chemical structure of butylcyanoacrylat, the monomer in PBCA.
Figure 2.4: The chemical structure of octylcyanoacrylat, the monomer in POCA.
Pegylation means to cover the surface with polyethylene glycol(PEG) (figure
2.6). This is done to create an hydrophilic surface to an otherwise hydrophobic
particle and will make the particle more biocompatible and lessen the chance
of provoking an immune response[54]. Naked NPs are of little use in biological
systems because they will rapidly bind proteins, both non-specifically and as a
part of opsonization and removal by the RES system[55]. Most often, the PEG
chain is part of a molecule that also has a non-polar part to make the molecule
organize in the oil-water interphase and act as a surfactant. In this project, both
covalently linked PEG and PEG held in place by hydrophobic interaction have
been used. Because BCA polymerizes easily, surfactants with reactive groups
can easily initiate polymerization. Described in the following paragraph are the
surfactants and initiators used for the PBCA NPs in this project.
BRIJ 35 (figure 2.7) is a simple, non-reactive surfactant that will be attached
to the oil water interphase by hydrophobic interaction. Compared to other sur-
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Figure 2.5: Anionic polymerization of butyl cyanoacrylat.
1. A group containing a free electron bind the CH2 group, and the free electron
is moved to the central C atom.
2.This C atom now has a free electron (negative charge) and can act on a neighbor
BCA molecule.
3.The R group started a chain reaction leading to polymerization of the BCA
molecules.
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Figure 2.6: The chemical structure of polyethylene glycol (PEG).
factants, BRIJ 35 is easy to handle and is added to the particle because it simply
organizes at the interphase without initiating polymerization. BRIJ 35 is at-
tached to the surface of the NP because of the long alkyl chain that will be
entangled into the polymer upon polymerization. The PEG chain in BRIJ is 23
units long (molecular weight= 23 ∗ 44g/mol = 1012g/mol).
Jeffamin M2070 (figure 2.7) is an initiator containing PEG that has been
attached to particles. Jeffamin has an amin group (NH3) on the hydrophobic
part of the molecule. This group is highly reactive and will initiate polymerization
and be covalently linked to the NP. The PEG chain in Jeffamin is 19 units long
(836 g/mol). Jeffamin is too reactive to use as a surfactant and is therefore added
to the solution after the nanoemulsion has been made.
Jeffamin
BRIJ 35
Figure 2.7: The chemical structure of Jeffamin and BRIJ 35, the two surfactants
covering the PACA NP.
2.3.3 Particle stability and poly ethylene glycol (PEG)
Controlling the stability and surface properties of NPs is vital. The particles must
have a sufficient shelf life in solution as well as controllable properties in biological
environments. The life of a NP consists of multiple destabilizing mechanisms and
forces. Both avoiding aggregation and premature degradation are important in
order to maintain function and safety of the product. Injecting particles above
5µm into the vascular system will lead to blocked capillaries and embolism, while
particle degradation may lead to drugs being leaked to the surrounding tissue or
solution[56].
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There are destabilizing mechanisms present in both solution and in biolog-
ical environments. In solution, charged particles are generally effected primar-
ily by two opposing forces; electrostatic repulsion and Van der Waals attractive
forces[52]. Particles of similar charge will repel each other, but this surface charge
is in solution screened by the electric double layer (EDL) of counter ions that build
up on the particle surface. This phenomenon is described by the Gouy-Chapman
model[52], where counter ions are divided into two layers. The inner layer is
called the Stern layer, and is immobilized on the particle surface. The surface of
the outer layer is called the slipping plane, here the ions move around, but are
by electrostatic attraction bound to the proximity of the particle surface. This
model is presented in figure 2.8. The effective surface potential is measured at
the slipping plane and is called the zeta potential. A higher zeta potential will
give more stable particles, and a value of |ζ| > 30mV is generally considered to
give stable particles[52].
Figure 2.8: Illustration of the electric double layer. Adapted from [57].
In biological fluids, the particles will meet a high concentration of electrolytes
as well as a variety of proteins. While a high electrolyte concentration will de-
crease the Stern layer and hence let other particles and proteins closer to the
particle surface, proteins in for example blood serum will adsorb to anything
unfamiliar[29]. The proteins on the particle surface will define the biological
identity of the particle which is different to the synthetic identity. A NP might
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change and become very different in terms of size, shape and surface properties
once presented to biological environments[55]. Some proteins in blood are part
of the innate immune system and are specifically designed to bind to foreign
particles to help monocytes and macrophages performing phagocytosis[29].
Pegylation is a common strategy to avoid adsorption of proteins on the par-
ticle surface. In solution, this will also increase the stability by creating a steric
repulsion but decrease the zetapotential. Decreasing the zetapotential is ben-
eficial to avoid protein attaching to the NP[58]. A relatively recent study has
shown that the rate of particle uptake by macrophages are indeed increased if
the particles have adsorbed proteins to their surface, and also show that this
effect can be limited by PEG (figure 2.9)[59]. The figure illustrates how the in-
creasing density of PEG on the particle surface will limit the amount of proteins
adsorbed. This will make the uptake in macrophages more dependent on serum-
independent phagocytosis which is less effective than serum-dependent uptake.
From the figure one can also see how the conformation of PEG changes with
increasing concentration.
Figure 2.9: Illustration of protein adsorption and macrophage uptake dependent
on PEG density. With high PEG density, the macrophage uptake is more driven
by the less effective serum independent process, and the total particle uptake is
reduced. Adapted from [59]
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2.4 Cellular uptake of nanoparticles
2.4.1 Uptake mechanisms
Most cancer drugs works intracellularly, this means that the drug must be taken
up by the cell to cause the desired effect[60]. To engineer the NP it is important to
have detailed knowledge of the internalization mechanisms and the intracellular
routing of the drug and NP. While ions, some small proteins and molecules such
as glucose and amino acids are transported through the membrane by specialized
transporter proteins[25], larger substances such as NPs are too big for the spe-
cialized transporter proteins, and are internalized through endocytosis[61][62][63].
Endocytosis is a number of mechanisms that involves folding the plasma mem-
brane into vesicles that are released from the membrane, and transports it con-
tents into the cell[25]. The opposite, where intracellular vesicles are fused with
the cell membrane to release the contents extracellularly is termed exocytosis.
Endo- and exocytosis are important for many of the cells vital processes such as
uptake of nutrients, transcellular transport, signal transduction and phagocyto-
sis. Also, this process is important for transporting membrane bound proteins
such as receptors, transporter proteins and signaling molecules[64].
Endocytosis is divided into two subgroups, phagocytosis and pinocytosis.
Phagocytosis is mainly performed by professional phagocytes; macrophages, mono-
cytes neutrophils and dendritic cells. These are all part of the innate immune
system where phagocytes can internalize whole bacteria and cells with a size up
to tens of micrometers[62]. Phagocytosis occurs only after the object has been
opsonized, that is the cell/bacteria/particle has been covered by proteins such has
immunoglobulins and complement components. These proteins are recognized by
the phagocytes prior to phagocytosis[65].
Cancer cells would internalize nanoparticles through pinocytosis. Pinocy-
tosis can further be dived into subgroups, macropinocytosis, clathrin-mediated
endocytosis (CME), caveolin-mediated endocytosis, and clathrin- and caveolin-
independent endocytosis. The five different endocytotic pathways, phagocytosis
included, are illustrated in figure 2.10.
Clathrin-mediated endocytosis
The best understood endocytosis mechanism is CME. This is also believed to be
the most important mechanism for internalization of nutrients and macromolecules[25],
and many of the principles involved in CME also apply to the other pinocytotic
pathways[66]. CME is receptor mediated, meaning that the substrate to be in-
ternalized must bind to a surface receptor. Multiple receptors will bind to bigger
objects and create an area concentrated with receptors. These areas will be cov-
ered by an adaptor complex AP2 and clathrin, a triskelia-shaped macromolecule,
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Figure 2.10: The different endocytotic pathways in a mammal cell. The pathways
differ in size and mechanism of vesicle formation. Adapted from [66].
on the cytosolic side[67]. CME is illustrated in figure 2.11. Clathrin and AP2
will create curvature in the membrane, which continues as further clathrin and
AP2 are connected. Eventually, a vesicle will be formed which is cut of from the
membrane by a complex of dynamin proteins.
Caveolin mediated endocytosis
Caveolin mediated endocytosis is the main mechanisms of endocytosis after CME.
Vesicles are formed by caveolin-oligomerization in the plasma membrane which
creates an invagination and eventially, a flask-shaped vesicle. The vesicle is cut
of from the membrane by dynamin 2. Caveosomes are vesicles with a neutral pH
that can fuse with early endosomes or fuse directly with lysosomes[68].
This endocytosis mechanism is generally thought to capture smaller volumes
and particles with a diameter around 60nm[66], and mainly work to internal-
ize lipid rafts of cholesterol or sphingolipids, the actual endocytic capability is
disputed[69]. However, it has been reported that for beeds above 200nm, cave-
olin is involved in a uptake superior to CME and also some pathogens enter cells
through this mechanism[63]. Larger objects internalized through caveolin me-
diated endocytosis have been shown to have no colocalization with lysosomes,
indicating that material taken up through this pathway escapes lysosomal degra-
dation.
Clathrin- and caveolin independent endocytosis
Cellular uptake can also occur through macropinocytosis, which is large ruﬄes in
the cell membrane folding over to create a vesicle. This mechanism is not selective,
meaning that it does not depend on receptors or stimuli from the internalized
material. Macropinocytosis also occurs at a relatively constant rate in most cells
and serves as a method for sampling the environment[70].
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Figure 2.11: Illustration of CME. The internalization of receptor-bound molecules
is exemplified by transferrin and the transferring receptor. AP2 and clathrin cover
the cytosolic side of the cell membrane, and creates the invagination. A dynamin
complex then assembles at the neck of the forming vesicle and cuts it of from the
plasma membrane. Illustration adapted from[66].
Other endocytosis mechanism independent of both clathrin and caveolin have
been discovered. Both dynamin- dependent and independent processes have been
found, but they have in common a relatively limited size and often require the
assembly of lipid rafts in the membrane[25].
Inhibitors of endocytosis
In order to study mechanisms of endocytosis, the different pathways can be selec-
tively inhibited. This is achieved biologically by blocking one of the critical steps
in vesicle formation. Chlorpromazine is such a pharmaceutical that selectively in-
hibits CME by blocking the recruitment of clathrin the plasma membrane hence
limiting the formation of clathrin coated vesicles[71]. Genistein inhibits caveolin
mediated endocytosis by disrupting the local actin network and limiting the re-
cruitment of dynamin[72]. All forms of endocytosis can be inhibited by cultivating
at 4°C[73].
Endocytosis inhibitors are effective tools for studying uptake mechanisms, but
it is important to be aware of some limitations of the technique. The effect and
also cytotoxicity of various inhibitors is cell line dependent, and many inhibitors
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have selectivity issues[74][61].
2.4.2 Intracellular route
After internalization, the newly formed vesicle will fuse with hydrolase containing
vesicles from the Golgi complex to create early endosomes[25]. This process is
rapid, the vesicle is typically formed within 2 minutes and fusing with vesicles
from Golgi will occur for approximately 10 minutes[75][64]. The early endosomes
become late endosomes when the pH is dropped towards 5 and they loose the
ability to fuse with endocytic vesicles. After 10-40 minutes, the late endosomes
fuse with lysosomes[76]. After being degraded in the lysosomes, the material can
either be removed from the cell by exocytosis, delivered to specific organelles
or be released in cytosol. Possible routes for endocytosed NPs are illustrated in
figure 2.12. Evaluating the possible lysosomal escape and drug delivery to cytosol
using NPs is highlighted as a main challenge in a recent review article in ACS
Nano[77]. A group studying delivery of siRNA using lipid NPs found that only
1-2% of the siRNA was able to escape endosomal vesicles[78].
Figure 2.12: The uptake and possible intracellular routes of NPs, illustration
adapted from [79].
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2.4.3 Cellular uptake of nanoparticles
Characterizing the uptake of NPs is important in order to understand how NPs
can help deliver drugs inside the cell. Due to the huge range of NPs with regards
to size, material, shape, electric charge and surface modifications, this is a vast
field of research, mainly the uptake of polymeric NPs will be described in this
section. The study of uptake kinetics of polymeric particles is challenging due
to the degradability of the particles. In a master thesis from spring 2013, Sofie
Snipstad studied the same particles that are being studied in this master thesis,
and found that the uptake was very high after only a few minutes. However, the
thesis concluded that this was due to contact mediated uptake of the fluorescent
dye that leaked from the NP[80]. In most polymeric particles, the fluorescent
dye is spread in the polymer and can therefore either leak from the particle, or
be gradually released as the particle is degraded. It is therefore important to
separate uptake of free dye to the uptake of actual particles[81].
PBCA particles with sizes from below 60nm and up to 250nm were studied
by Weiss et al.[82]. They found that particles around 60nm was taken up at
a higher rate than those bigger, but also the largest particles (250nm) had a
significant uptake after less than 10 minutes in both Jurkat and HeLa cells. The
paper conclude that the two cell lines react differently to changing particle size
and surface modifications. However, images presented in this paper suggest that
also free dye is taken up by the cells. The dependency of surface molecules on
uptake are also seen in other papers[83][84] where the surfactants polysorbate-80
and poloxamer 188 are seen to increase the uptake of polymeric NPs.
2.5 Experimental techniques
2.5.1 Fluorescence and fluorescent probes
Modern analysis methods such as flow cytometry (FCM) and fluorescence mi-
croscopy depends heavily on labeling structures with fluorescent molecules. This
can assure selectivity to FCM measurements and specificity and high resolution
in imaging. A fluorescent molecule will emit light at a longer wavelength than
the wavelength used to excite the molecule. An exception is multi-photon exci-
tation where multiple photons combine their energy to create an excited state
with typically 2 or 3 times the energy of a single excitation photon[85]. The
excitation and emission process is often illustrated with a Jablonski diagram as
seen in figure 2.13. Within an energy band, the electron will rapidly decay to the
lowest vibrational state within that band. The energy of the emitted photon will
therefore be lower than the energy of the excitation photon. From the excited
state there are multiple decay mechanisms back to the ground state, both radia-
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tive (Γ) and non-radiative(κ) where only the radiative decay results in detectable
photons emitted by the fluorophore [86]. The amount of light emitted from a
fluorophore depends on the fraction of radiative decay termed the quantum yield
Q defined in equation 2.1.
Q = ΓΓ + κ (2.1)
Fluophores with high quantum yield is desirable as the same signal intensity can
be obtained at a lower laser intensity.
The wavelength λ of the photons are given from the photon energy through
equation 2.2 where ν is the frequency, h is the Planck constant, and c is the speed
of light.
E = hν = hc
λ
(2.2)
Figure 2.13: A Jablonski diagram describing the excitation from the S0 state and
possible relaxation mechanisms from the exited states. The horizontal lines within
the states illustrate vibrational states. The lifetimes of the various relaxation
mechanisms are indicated. Adapted from [87].
Another important property of the exited state that is used specifically for
fluorescence lifetime imaging (FLIM) is the lifetime τ . Through the different
decay mechanisms, the population of electrons in the exited state N(t) will decay
and in the simplest case follow an exponential decay from equation 2.3
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N(t) = N0e−
t
τ (2.3)
where N0 is the initial number of fluorophores in the exited state, t is time and
τ is the fluorescent lifetime given by equation 2.4.
τ = 1Γ + κ (2.4)
Some fluorophores, including NR668 used in this thesis have a two-exponential
decay where the fluorescent signal is given by equation 2.5[88][89].
F (t) = A1e−
t
τ1 +A2e−
t
τ2 (2.5)
Here, A1 and A2 is the amplitude of the components, and τ1 and τ2 is the lifetimes
of the corresponding excited states.
NR668-modified nile red
The fluorescent dye used in this thesis to detect the NPs is a novel form of
nile red termed NR668[90]. Nile red is an old fluorescent dye, first developed
by Greenspan et al to stain intracellular lipid droplets[91][92]. The chemical
structure of conventional nile red and NR668 is seen in figure 2.14, where the
modifications of NR668 from conventional nile red are the alkane chains making
it more hydrophobic. Conventional nile red is hydrophobic, but it has been seen
that it will leak from the particles[93][80].
Figure 2.14: The chemical structure of nile red and NR668. Adapted from [90].
In FLIM, NR668 exhibits a double-exponential decay. The related physics
is not fully understood, but it has been proposed that these double exponential
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decays can occur due to the formation of either a twisted intramolecular charge
transfer (TICT) state[94] or a solvent relaxed state[95]. The double exponen-
tial decay for conventional nile red is well documented [95][89], and due to the
structural similarity, the explanation is most likely valid also for NR668. The
TICT state is formed by conformational changes at a point where the fluorescent
molecule has rotational freedom. NR668 has rotational freedom at the−N(Hex)2
bond. It has been found that the fluorescence lifetime of conventional nile red
encapsulated in various polymers depends on the elastic modulus of the polymer,
but that two lifetimes are seen, a short lifetime varying from 0.55 ns to 1.4 ns
and a long lifetime varying from 1.2 ns to 4 ns[89]. The short lifetime is from the
initially excited state while the long lifetime results from either a TICT state or
a solvent relaxed state[95].
2.5.2 Confocal laser scanning microscopy
Confocal laser scanning microscopy (CLSM) is the most popular technique for
imaging of biological samples due to its high resolution both axially and radially
and the limited invasion of the sample. The method is an evolution of wide field
fluorescence microscopy where the resolution has been significantly improved by
placing a pin hole at the conjugate plane in front of the detector and scanning
the sample[96]. The pinhole removes signal from out of focus regions which is
a limiting factor in wide field fluorescence microscopy where fluorescence occurs
throughout the excited volume. CLSM uses lasers to selectively excite either
endogenous fluorescence molecules in the sample, or fluorescent probes added[97].
A schematic illustration of the optical path in a CLSM is seen in figure 2.15.
A modern CLSM is normally an integrated system offering multiple detectors,
objective lenses and lasers. The sample is scanned by the scan head and a software
is used to create and analyze the image. The general concept is that the laser
beam is focused onto the sample by the objective lens. Light emitted by the
sample then travels back trough the objective lens, is separated from the optical
path of the excitation laser by a dichroic mirror, focused through either a square
or a circular confocal pinhole, and often amplified by the detector, for example
a photomultiplier tube[98]. In the illustration (figure 2.15) it is seen how signal
from outside the focal plane is rejected by the pinhole.
The maximum resolution achievable, which will depend on the focal volume
will depend on multiple parameters such as laser wavelength, scan speed, objec-
tive characteristics and eventually the sample[99]. The focal volume typically
ranges from 0.25 to 0.8 µm laterally and 0.5 to 1.5 µm axially. The theoretical
limit of resolution is set by the diffraction limit, which describes the smallest spot
you can focus a laser. This is described by formula 2.6 where λex is the wave-
length of the excitation laser, NA is the numerical aperture and FWHM is the
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Figure 2.15: Illustration of the optical path in a CLSM. Adapted from [80].
width of the spot where the intensity is above half of maximum[100]. The NA
is typically around 1.2 giving a maximum resolution of 212 nm. This is valid if
the pinhole is equal to or bigger than one airy unit(AU), with a smaller pinhole,
slightly better resolution is possible. With a pinhole smaller than 0.25 AU, the
factor is 0.37 rather than 0.51
FWHM = 0.51λex
NA
(2.6)
With extra equipment connected to the CLSM, other imaging options are
available. Non-linear imaging is possible, and describes a system where the flu-
orophore is excited by multiple photons where each have a lower energy than
the emitted photon. For example two-photon excitation where a high intensity
laser of λ ≈ 800nm can excite fluorophores with excitation peak around 400nm.
Other analysis possible with CLSM is spectral analysis and fluorescence lifetime
imaging (FLIM). Spectral analysis can include both varying the excitation wave-
length, and measuring the fluorescence signal at different emitting wavelength.
This can give valuable information if the specter from the emitter depends on
the local environment. FLIM uses a separate set of detectors and software and
is described in more detail in the following section.
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2.5.3 Fluorescence lifetime imaging
Fluorescence lifetime imaging (FLIM) is based on an external system coupled to
CLSM. The idea is to measure the lifetime of the excited state of the fluorophore.
This can give valuable information because the lifetime will often depend on the
local environment[101].
FLIM is normally divided into two categories, time domain (TD) and fre-
quency domain (FD). Although these two approaches are theoretically equivalent
and related through their Fourier transform, they offer different advantages. FD
FLIM have the advantage of using a continuous light source which is generally
cheaper. FD is also reported to obtain higher resolution for multi exponential
decays[86]. TD has the advantage of being a more intuitive and flexible system
and being capable of measuring a wide range of lifetimes. TD is the system
offered at NTNU department of physics that was used during this thesis.
For TD FLIM, the sample is scanned using a pulsed laser source. A schematic
of the setup is seen in figure 2.16. The beam is split in two parts, where one part
is sent directly to the detector as a reference time point, the other part is used
to excite the sample. The lifetimes are evaluated using time-correlated single
photon counting (TCSPC). In TCSPC, only the first photon emitted after each
excitation is detected. Depending on the time delay between the reference signal
and the photon from the sample the photon will fall into an interval, by collecting
many photons, a time correlated histogram is constructed[102].
Figure 2.16: The setup of TD FLIM. PD = photodetector, PMT = photomulti-
plier tube. Illustration adapted from [103].
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In an ideal case, the sample is excited by a delta (δ) pulse. In reality the
excitation pulse has a curved intensity distribution, which gives rise to noise to
the detected signal. This is corrected for using and instrument response function
(IRF). This function is measured and the function describing the observed decay
is a convolution of the IRF and the exponential decay. For a two-exponential
system as seen with nile red in this thesis, the decay function F (r, t) is given
as[86]:
F (r, t) = E(t) ∗
2∑
i=1
Ai(r)e−
t
τi(r) (2.7)
Here, E(t) is the IRF, A is the amplitude and τ is the fluorescence lifetime.
To simplify calculations and graphical representations, the dual lifetime is often
reduce to the average lifetime using
τave =
α1τ
2
1 + α2τ22
α1τ1 + α2τ2
(2.8)
where α1 and α2 are the amplitudes of the two lifetimes τ1 and τ2.
2.5.4 Flow cytometry
Flow cytometry (FCM) is a quantitative method used in this thesis to measure
the amount of NR668 and by that the number of NPs inside the cells. Generally,
FCM can be used to separate various cell types in a solution such as blood, per-
form live-dead assays in toxicity studies, or measure multiple dyes inside single
cells. For FCM, the cells must be in solution. Using a mechanism termed hy-
drodynamic focusing where a jet stream of sheet fluid creates a focused stream
with room for only one cell at the time, the stream of cells is directed through
a laser beam orthogonal to the fluid stream, where the cells are illuminated and
fluorophores are excited. The scattered light from the cells are detected both in
front of the cell (forward scattering detector (FSD)) and to the side (side scatter
detector (SSD)). The forward scatter will depend on the cell size where smaller
cells will scatter less while the side scatter will measure the granularity of the
cells. More granular cell content will result in more side scattering[104]. The
emitted light from fluorophores is also detected, spatially separated from the ex-
citation beam[105]. Using dichroic mirrors and multiple fluorescence detectors it
is possible to quantify multiple fluorescent dyes for each cell.
Data obtained from FCM is relative, and control samples must be included
in each analysis. In an uptake study, cells incubated under the same conditions
but not incubated with NPs must be included to measure the autofluorescence
of the cells. This way, it is possible to present data as histograms of the sample
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Figure 2.17: Illustration of the general setup of a flow cytometer. Adapted from
[106].
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and the control. In figure 2.18, FCM histograms showing the cellular uptake
of POCA particles are shown. As the label in the right corner indicates, the
red histogram presents the untreated cells (control). The two other histograms
present are cells incubated with NPs for 3 hours (purple) and 24 hours (blue).
The X-axis represents the fluorescence intensity. The gate labelled #1 indicates
a selected area, and the percentage of cells from each sample found within this
area can be red out from the numbers below.
Figure 2.18: Example of histograms obtained from FCM. The figure shows the
uptake of POCA NP’s in PC3 cells after 3 hours(purple) and 24 hours(blue). The
red histogram is from control cells not incubated with particles, but otherwise
treated identically.
Chapter 3
Materials and methods
3.1 Cell cultivation
3.1.1 Cell medium
The medium used for cell cultivation was Dulbecco’s modified eagle medium
(DMEM, Gibco Life Technologies) supplemented with 10% fetal bovine serum
(FBS, Sigma Aldrich). This will be referred to as DMEM 1. For long incubation
times with NPs, DMEM with 10% FBS and 50mg streptomycin penicillin (Sigma
Aldrich) was prepared, this will be referred to as DMEM 2.
3.1.2 Cell cultivation
In this master thesis, prostatic adenocarcinoma cells (PC3, American Type Cul-
ture Collection) were used for all experiments. The batch of cells was changed
once (15th of march) to assure original properties.
The cells were cultivated in 75 cm2 cell culturing flasks (Nunc) with 15mL
DMEM 1, incubated at 37°C with 5% C02 and kept in the exponential growth
phase. 1-2 million cells were transferred to the new flask, splitting was done every
third or fourth day.
The cells were split by removing the medium and gently washed with 5 ml
sterile phosphate buffered saline (PBS, Sigma Aldrich). PBS was then removed
and 3 mL of 0.25% trypsin and 0.2% EDTA (Sigma Aldrich) was added to detach
the cells from the incubation flask. The trypsin was allowed to work for 3 minutes
at 37°C before the trypsination was stopped by adding 8 mL cell medium to the
flask. 10 ml of this mix was added to a Falcon tube and centrifuged (Heraeus
Megafuge 1.0) at 1500 rpm for 5 minutes. 10 µL of the solution remaining in the
cell flask was mixed with 10 µL trypan blue (Molecular probe, Life Technologies).
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The concentration of living cells was then analyzed using a cell counter (Countess,
Invitrogen).
After centrifugation, the cells were resuspended in cell DMEM 1 to a concen-
tration of 1E6 cells/mL. Then 1-2 million cells were passaged to a new flask. The
remaining cells were either used for experiments or discarded. Back up of cells
in case of infection was done either by cooperation with others working with the
same cell line, or by keeping a second flask of cells. During the cultivation of
cells, the medium was normally changed once during every passage.
3.2 Nanoparticles
The NPs used in this project are PBCA (poly(butylcyanoacrylat)) and POCA
(poly(octylcyanoacrylate)) made by SINTEF materials and chemistry. The NPs
are made through polymerization in a oil in water nanoemulsion. The general
steps in this process are listed below while the general setup is shown in figure
3.1
1. The molecules that will end up in the NP are mixed in an oil in water
emulsion. The droplets are stabilized by a surfactant (BRIJ-35). The oil
phase consists of a monomer (butyl/octyl cyanoacrylate), a co-stabilizer
(Miglyol 810N, a neutral, very hydrophobic oil), an initiator, and other
molecules that you want in your particle (fluorescent molecules, cytotoxic
drugs, etc.) The surfactant will organize at the oil-water interface, while
the co-stabilizer will prevent Oswald ripening. The water phase is kept at
acidic conditions to avoid premature polymerization.
2. An initiator (Jeffamin) is mixed into the solution and an ultrasound probe
is used to make a nanoemulsion. The energy from the ultrasound creates
nanometer droplets from the micrometer droplets in the emulsion.
3. The initiator starts the polymerization and the nano droplets polymerize.
The different NPs used, monomer, diameter, zetapotential and stability at pH
7.4 are listed in table 3.1.
Table 3.1: List of NPs used, adapted from [7] [8].
Particle Monomer Diameter Load Zeta poten-
tial (ζ)
Halflife at
pH 7.4
Targ 67 BCA 177nm NR688 -12 20 hours
Targ 76 OCA 151nm NR688 -10 stable
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Figure 3.1: The general setup for making NPs through an oil in water emulsion.
Adapted from a presentation by Yrr Mørch SINTEF Materials and chemistry.
3.3 Flow Cytometry analysis
The cellular uptake of NPs was quantified using FCM. PC3 cells were seeded
in 12 well plates (COSTAR). The 1E6 cell/mL solution from splitting the cells
(section 3.1) was diluted to a concentration of 125000 cells/mL. 1mL (125000
cells) was added to each well and the cells were cultivated at 37°C and 5% CO2
for 2-4 days.
To incubate the cells with NPs, solutions of 20µg/mL of NPs in DMEM 1
was made prior to incubation. The cell medium in each well was then removed
and either DMEM 1 (reference cells), or DMEM 1 with NPs was added to the
wells. This was then cultivated at at 37°C and 5% CO2 for the desired time.
After incubation with NPs, the cells were prepared for flow cytometry. The
medium was removed from the wells, and the cells washed with 400µL PBS(Sigma
Aldrich). This was removed, and 300µL of trypsin solution was added to the wells.
The cells were left at 37°C for 3 minutes before the trypsination was stopped by
adding 700µL DMEM 1 to each well. The solution from the wells was collected
in separate falcon tubes and centrifuged at 1500 rpm for 3 minutes. The cells
were then washed with cold PBS twice before they were resuspended in cold PBS
and stored on ice. Before running flow cytometry, the cells were transferred to
FCM tubes.
The cells were analyzed by FC (Gallios, Beckman Coulter). The dye in the
particles used was modified nile red (NR688). A λ = 561nm laser was used to
excite the particles which was detected at λ = 630nm using a 30nm bandpass
filter. The voltage was set to place the unlabeled reference cells from 0-1 (first
decade) on a log scale in terms of fluorescence intensity. Using a forward scatter
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versus side scatter diagram, dead cells and aggregates were gated out and 10000
healthy cells were counted for each sample.
3.3.1 Endocytosis inhibitions
For inhibition studies, stock solutions of Chlorpromazin and Genistein were made;
• Chlorpromazin 5mg/mL in FBS.
• Genistein 10mM in DMSO.
Prior to each experiment, the solutions were diluted in DMEM 1 to a final con-
centration of 10µg/mL (Chlorpromazin) and 50µM (Genistein).
Cells were pre-incubated with the inhibitor for one hour before NP’s were
added. Inhibition experiments had three hours incubation with NP’s. The pro-
tocols for inhibition with Chlorprozin[107] and Genistein[108] was found in the
literature.
For the 4°C experiment, the cells were pre-incubated at 4°C for 10 minutes
before cold particle solution was added. The cells were then stored at 4°C until
the measurement.
3.4 Confocal laser scanning microscopy analysis
3.4.1 Preparation
Cells to be analyzed with CLSM were grown in 8-well imaging plates (Ibidi). The
cells were diluted to 62500 cells/mL in DMEM 1, and 300 µL(18750 cells) were
added to each well. The cells were cultivated at 37°C and 5% CO2 for 3 days
prior to imaging. Before imaging, the media was replaced with fresh DMEM 1.
3.4.2 Incubation with nanoparticles, free NR668 and stain-
ing for early endosomes and lysosomes
Solutions of 20 µg/mL of NPs in DMEM 1 was made. After removing medium
from the wells, 300 µL of this solution was added to each well at the required
time point. The cells were then left 37°C and 5% CO2 until imaging.
Cells were also labelled with free NR668. A stock solution was made by
dissolving 2.6 mg NR668 in 10 ml DMSO (dimethyl sulfoxide). Before use, the
solution was further diluted 1:10000 in DMEM 1 to a final concentration of 26
ng/mL.
Staining for early endosomes was done to study colocalization with NPs and
early endosomes. The early endosomes were marked using CellLight®Early
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Endosomes-GFP with excitation and emission maxima of 488nm and 510nm.
A solution of 40 virus particles/cell was prepared in DMEM 1 and added to cells
24 hours before imaging.
Staining for lysosomes was done with Lysotracker®Blue (Life Technologies).
Due to very weak staining, the concentration was increased from 75 nM as sug-
gested in the manufacturers protocol to 2.5 µM . The dilution from Stock solution
of 1mM was done in DMEM 1, and the solution added to the cells 1 hour before
imaging. The excitation and emission maxima of Lysotracker®Blue is 373 nm
and 422 nm.
3.4.3 Imaging
For imaging of the NPs and cells, the SP8 microscope was used with a 63x1.2
water objective with a motCorr coverslip. The pin hole was set to 1 airy unit. For
excitation, a white light laser at 514nm was used and the signal detected from
580nm to 660nm using the HYD-3 detector. Bright field images was created using
the 514nm laser and detecting with the PMT detector using a transmitted light
filtercube.
3.4.4 Colocalization imaging
For colocalization, controls of cells incubated with either fluorescent stain (Lyso-
tracker®Blue or CellLight®) or NP’s were used to adjust laser and detector
wavelengths to avoid cross-talk between channels. The images were recorded in
a sequential scan, this also to reduce potential cross-talk.
Lysotracker®Blue was excited using a pulsed multiphoton laser at λ = 746nm,
CellLight®was excited at 488nm.
3.4.5 Fluorescence lifetime imaging
For fluorescence imaging, the SP8-FLIM FCS APD SPADS mode was selected
on the SP8 and the coverslip/Corring adjusted for minimal reflection, typically
around 93-96. The sample was excited at 514nm at a 40MHz repetition rate
and detected using the SPAD 2 detector (565-615nm). The FLIM was done
with maximum resolution, 512x512 pixels. Pico Quant Sympho time was used to
record and analyze the lifetimes.
Analysis of the lifetimes was done both by extracting the .dat file to Excel
and in the PicoQuant software. In Excel, the maximum recorded intensity in the
images was used to normalize the images, making them comparable. Averages
from 5 FLIM images were then calculated to produce lifetime distributions.
In PicoQuant, the internally recorded IRF-function convoluted with a two-
exponential decay function was used to fit the resulting decay curve. Regions of
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interest (ROIs) were manually selected based on the color labeling in the original
FLIM image. The areas were chosen large enough to obtain a peak value of
approximately 1000 photons.
3.4.6 Spectral analysis
For spectral analysis, a 514nm laser was used as excitation light, and the emitted
light detected in overlapping areas of 10nm starting from 550nm and running to
700nm. The areas had a 5nm overlap resulting in 30 areas for each sample. To
analyze the data, the .csv files were extracted and analyzed in Excel.
3.4.7 Triton treatment
Triton X-100 (Tx100) was diluted to 10% in DMEM. 15µL of this solution was
added to the Ibidi well during imaging. Prior to adding the Tx100 solution, the
SP8 microscope was programmed to take an image every second using 514nm
excitation and detecting from 600nm to 680. It was normally recorded approxi-
mately 10 seconds prior to adding Tx100 and 3 minutes after adding Tx100.
3.5 Statistical analysis
Statistical analysis was done using the t-test function in Excel. P-values below
0.05 are considered significant.
Chapter 4
Results
The results have been divided into two separate parts, one presenting the cellular
uptake and the other presenting intracellular degradation of the PACA NPs. The
particles used are described in table 3.1 in section 3.2, and will be referred to as
PBCA (Targ 67) and POCA (Targ 76). The cells used were human prostate
cancer cells (PC3).
4.1 Cellular uptake of nanoparticles
4.1.1 Initial uptake studies
Before uptake of POCA and PBCA particles can be compared, one have to mea-
sure the relative intensity of fluorescent emission from the two particles. This was
done prior to this work by Eva von Haartman and Andreas A˚slund, the result is
presented in the appendix part A. It was found that at an emission wavelength
of 561 nm, the wavelength used for FCM, PBCA NPs were more fluorescent than
POCA particles by a factor of 1/0.52 = 1.923. In studies were these two particles
are compared quantitatively, the fluorescence of cells with POCA particles has
been multiplied by this number.
Initially, uptake studies with FCM were performed. PC3 cells were incubated
with PBCA and POCA NP for 3 and 24 hours at 37 °C. The resulting histogram
from one of the parallels is seen in figure 4.1. The shift in mean fluorescence
after 3 and 24 hours is presented in figure 4.2, both calculated from 3 different
experiments (A), and calculated from 3 parallels within the same experiment
(B). It can be seen that after 3 hours, the cellular uptake of POCA NPs is 3-
10 times higher than the uptake of PBCA, after 24hours, there is no distinct
difference. It can also be seen that the standard deviation between separate
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experiments are generally higher than the standard deviation between parallels
in one experiment. In FCM, 10000 healthy cells were recorded, but further gating
reduces the effective amount to 7000-9000 cells.
Figure 4.1: Representative logarithmic FCM histogram of uptake of POCA and
PBCA NP by PC3 cells.
Figure 4.2: The relative change in mean fluorescence of PC3 cells incubated with
POCA or PBCA NP for 3 and 24 hours. The values and standard deviations in A
are calculated from 3 different biological experiments while B is from 3 parallels
in one experiment. The difference in fluorescence intensity has been accounted
by multiplying the the values from POCA by the normalization factor 1/0.52
It was confirmed that the particles where inside the cells using CLSM. Figure
4.3 shows three images from a z-stack of cells that has been incubated with POCA
NP for 24 hours. The images show that the particles are found inside the cell,
but generally not within the cell nuclei. The same thing was seen for the PBCA
NP (not shown).
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Figure 4.3: Three images from a Z-stack of PC3 cells and POCA NPs. NPs are
colored red. A: top of the cells, B: the middle of the cells, C: the bottom of the
cells. Scalebar: 10µm
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To gain more detailed information on the uptake of the NP, the uptake from
0-3hours was further evaluated, the result is seen in figure 4.4. The curve shows
the that POCA is taken up more rapidly than PBCA.
Figure 4.4: Cellular uptake of POCA and PBCA NP in 0 to 3 hours. The numbers
are normalized to the different initial fluorescence intensity, autofluorescence has
been subtracted.
Images were also taken of cells incubated with PBCA and POCA NPs for 24h
to verify the amount of uptake, this is seen in figure 4.5. Here, it can be seen that
after 24 hours, a large uptake of both POCA and PBCA particles has occurred.
The amount of particles in the cells is relatively similar for the two images.
4.1.2 The effect of incubation conditions and pre-treatment
of the nanoparticles on cellular uptake
The uptake of NPs presented in the results above was high compared to previous
experiments performed fall 2013 by a visiting phd student, (unpublished results),
and the difference between POCA and PBCA had not been previously observed.
Further control experiments were therefore performed in order to better under-
stand the parameters affecting the rate of uptake.
It was investigated if the cell medium or the cells affected the NP making them
either more or less easy to internalize for the cells. POCA NPs were pre-incubated
for 21 hours in two different environments:
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Figure 4.5: CLSM image of PC3 cells incubated for 24 hours with PBCA (A)
and POCA (B) NPs. Iex = 514 nm. Scale bar: 10 µm
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• In DMEM 1
• In DMEM 1 and PC3 cells growing in a cell culturing in flask.
Thereafter, the solution solutions were transferred to wells with PC3 cells.
Cells were also incubated with fresh POCA NP for 3 and 24 hours as control and
reference value. Figure 4.6 shows the resulting histograms while figure 4.7 shows
the mean fluorescence calculated from three parallels. An increased uptake of
63% is seen when the POCA particles have been incubated with other PC3 cells
for 21 hours prior to incubation, compared to untreated particles. The effect of
21 hours in pure medium (DMEM 1) is only minor.
Figure 4.6: Histogram showing the fluorescence of cells after incubation with
POCA NP stored under different conditions for 3 hours and cells incubated for
24 hours.
4.1.3 Effect of confluency/maturation of the cells
During the first set of experiments, it was observed that the cells would require
multiple days to fully settle after seeding. The term maturation describes the
time were the cells are cultivated after splitting, prior to measurements. It was
observed that within the first 5-6 days of maturation the cells would spread
more in the sample well and appear less rounded. It was therefore evaluated
whether maturation would effect the uptake of NP and if this could explain the
elevated uptake seen compared to previous experiments. Cells were seeded on
day 0, and the uptake of POCA NP was measured on day 2, 3 and 4. The
results seen in figure 4.8 show that the uptake increases with the number of days
of maturation. The cells were seeded at the same density, so the confluency
is also increased, approaching 95% on day 4. By gating the untreated cells at
approximately 2% positive, the positive population on day 2, 3 and 4 is 43%,
66% and 82% respectively, with the shift in mean fluorescence being more than
4 times higher on day 4 than on day 2.
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Figure 4.7: Mean fluorescence shift of cells incubated with POCA NP stored
under different conditions for 21 hours prior to incubation and cells incubated
with POCA NP for 24 hours as reference. Values are calculated from three
parallels, error bars showing standard deviations.
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Figure 4.8: The uptake of POCA NP after 3 hours of incubation growing 2
(A), 3 (B) and 4 (C) days in the 12well plate. The gate (labelled #1) is set
at approximately 1.8% false positive cells and captures 43.5%, 66% and 82%
respectively of the cells.
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4.1.4 Uptake mechanisms
To evaluate the uptake mechanism, cells were incubated with NP while suppressed
by endocytosis inhibitors. Chlorpromazin was used to inhibit CME, Genistein to
inhibit caveolin-mediated endocytosis. Also, cells were incubated with NP at 4°C
to clarify that the uptake was an energy dependent process. Figure 4.9 shows the
histograms of cells incubated at 4°C for 3 hours with POCA and PBCA, and con-
trol at both 4 and 37°C. The histograms are overlapping completely, indicating
no uptake of NP. The uptake under suppression of inhibitors is seen in figure 4.10.
4.10A shows that the uptake of POCA is reduced equally by Chlorpromazin and
Genistein indicating that both clathrin- and caveolin-mediated endocytosis plays
an important role in the uptake. In 4.10B the uptake is reduced by Chlorpro-
mazin, but hardly affected by Genistein. This indicates that caveolin mediated
endocytosis is less important for the uptake of PBCA particles. This experiment
was done twice to verify the result. The two experiments were done at different
time points after seeding to see if length of cultivation also affected the mecha-
nism. It was again found that the uptake was depending on time, but the effect
of inhibitors was the same in the two experiments. The histograms obtained
from the two experiments are found in the appendix part B. To make the two
experiments contribute equally to the histograms in figure 4.10, the fluorescence
shift from the experiment of low uptake was multiplied by the factor needed to
gain a similar maximum uptake of NPs without inhibitors.
4.1.5 Intracellular location of nanoparticles
In order to understand the environment faced by the particles once inside the
cell membrane, studies were done to look at the intracellular routing after entry.
This could also cast light on the uptake mechanisms, if the particles are taken
up by endocytosis, some colocalization with endosomes and lysosomes could be
expected. The intracellular location was mainly evaluated using different methods
available for CLSM. First, it was observed that the particles were inside the cell,
but not inside the nuclei (figure 4.3). Using Cell light GFP for early endosomes,
colocalization with this organelle was briefly assessed. It was found that the
staining gave fluorescence signal from most of the intracellular compartment,
making it hard to draw conclusions, this can be seen in the z-stack in figure 4.11
where green is GFP from early endosomes and red is NPs.
By carefully choosing suitable cells and reducing intensity post imaging the
image shown in figure 4.12 could be created showing a cell expressing GFP and
having POCA NP intracellularly. The white arrow points at possible colocaliza-
tion between an early endosome and a POCA particle.
Lysotracker blue was used to label lysosomes. Images of cells stained with
lysotracker and incubated with NPs were taken to look for colocalization. Figure
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Figure 4.9: FCM histograms of PC3 cells incubated for 3 hours at 4°C with
POCA and PBCA NP. Control both at 4 and 37°C are also shown.
Figure 4.10: Bars showing the relative mean fluorescence of PC3 cells incubated
for 3 hours with A: POCA and B: PBCA NP and suppressed by either Chlor-
promazin or Genistein. Calculations based on doublets from two different exper-
iments that has been normalized to the same maximum uptake of NPs and error
bars showing standard deviation.
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Figure 4.11: 3D model from a Z-stack of a PC3 cell transfected with Cell light
GFP marker (green) for early endosomes, the problem of diffuse staining is clearly
seen. Red spots are POCA NP .
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Figure 4.12: CLSM image of a PC3 cell expressing GFP on early endosomes after
incubation with POCA NP for 3 hours. The white arrow points out a spot of
possible colocalization between the particle and an early endosome. In the image,
background has been subtracted reducing the intensity in the green channel.
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4.13 shows a CLSM image of PC3 cells with lysosomes (green) POCA NPs (red)
overlaid a BF image. Yellow indicates that green and red are expressed in the
same pixel. The white arrows point at some of the yellow spots.
Figure 4.13: CLSM image of PC3 cells incubated with POCA NP (colored red)
for 3 hours and stained with lysotracker blue (colored green). Yellow indicates
that red and green are expressed in the same pixel, the white arrows points out
examples of this.
It was verified that the particles and lysosomes were colocalized by scanning
in the Z-direction. Figure 4.14 shows a Z stack of PC3 cells that has been sliced
were green (lysosomes) and red (POCA NP) are expressed in the same area
(white arrows). The bright field image has no transparency, so only particles and
lysosomes at the rim of the Z-stack can be seen.
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Figure 4.14: Z-stack of CLSM images of PC3 cells stained with Cell light GFP
for lysosomes and incubated with POCA NP for 3 hours. The channels are set
to have no transparency, so only the rim of the Z-stack is seen.
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4.2 Intracellular degradation of nanoparticles
It was initially though that looking for diffuse staining would be a possible method
of detecting intracellular degradation of NPs. However, as seen in figure 4.15, the
different particles and free NR668 look very similar inside cells after 24 hours of
incubation. Other methods were therefore tried in order to find ways of separating
NPs to free dye.
4.2.1 Fluorescence lifetime imaging
Initially, work was done to establish whether FLIM would be a sensible way
of detecting intracellular degradation. It would require that the fluorescence
lifetime of NR668 was depending on the local environment of the dye, and that
the differences were large enough the be readily measured. An initial literature
study suggested a two-exponential decay for conventional nile red that would be
different within for example different polymer materials[89]. Experiments were
therefore started by measuring the lifetime of NR668 within the particles and
finding a suitable protocol. The measurement conditions found are presented
in materials and methods (section 3.4.5). One important discovery was that at
some excitation wavelengths reflections from the sample well creates a devastating
artifact to the lifetime measurement. This effect can be imaged, and is presented
in figure 4.16 where (A) shows excitation at 488nm giving a bad case of ripples
from the sample well, while (B) shows excitation at 514 giving the optimum
imaging settings.
The first thing that was done was to measure the lifetime of NR668 inside
POCA and PBCA particles in solutions of different pH. This in order to both
look for potentially different lifetimes, and to see if the lifetime would change if
the particles were intact. The measurement was done by adding the solution to
an Ibidi well, and measuring the lifetime in the middle of the fluid volume. This
was done on fresh particles within 30 minutes of mixing the solution. The lifetime
measurement of fresh particles at different pH, measured in solution is seen in
table 4.1, and shows that the fluorescent lifetime does not depend on pH, but is
significantly different for the two particles with a P-value of 0.02 (short lifetime)
and 0.04 (long lifetime).
When measuring lifetimes in solution, like what was done in table 4.1, a
large contribution from the background limits the sensitivity of the measure-
ment. When possible, the proceeding FLIM measurements were therefore done
on particles either attached to the sample well or inside cells.
Particles were then stored in DMEM for 6 days. At this point the particles
will stick to the sample well, likely due to degradation of the PEG layer. The
measurement was done on a selection of particles in each image by choosing a
suitable ROI (region of interest). This method removes the background noise,
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Figure 4.15: Images of PC3 cells incubated for 24 hours with free NR668 (A and
B), PBCA NP (C and D), and POCA NP (E and F). NR668 and particles are
colored red. The images show that free NR668 and NPs are visually similar.
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Figure 4.16: Image of the sample holder at good and bad imaging setup. In A,
excitation wavelength is 488nm and in B the wavelength is 514nm, a wavelength
that was used for all proceeding FLIM measurements. The image is a XZ scan,
the green line is the sample holder. In image B, some NPs in the sample can be
seen below the green line.
but captures fewer photons than when measuring in solution. The results were
therefore calculated based on 6 images. FLIM images of particles attached to the
glass well indicated that the PBCA especially had a different lifetime in the core
of the particles compared to the shell, this is seen in figure 4.17. However, after
spectral analysis (section 4.2.2) it was found that scattering from the sample well
could be a problem when imaging the particles attached to the glass.
Figure 4.18 shows a CLSM image of PBCA NPs attached to the sample well
(A), the corresponding FLIM image (B) and a FLIM image where a selection
of particles has been chosen manually (C). The selected ROI’s are still colored
while the rest of the image is in black and white. The lifetimes collected from the
particles stored in medium for 6 days prior to imaging in solutions of different
pH are presented in table 4.2A. In table 4.2B, the significance calculated from
a student t-test comparing the numbers to the measured lifetimes in DMEM
is shown. These numbers can not be directly compared to those presented in
table 4.1 due to different measurement conditions. The average numbers are also
presented visually in figure 4.19. The results show that the lifetime of NR668 in
POCA particles remains essentially unchanged after changes to the environment
while inside PBCA particles, the lifetime changes.
A study was then started to look at the intracellular degradation of PBCA
and POCA, and to see if lifetime measurements could cast some light upon this
52 CHAPTER 4. RESULTS
Figure 4.17: FLIM of PBCA (A) and POCA (B) attached to the sample well.
Arrows point at particles where the core have a different, shorter lifetime than
the shell of the particles.
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Figure 4.18: Images showing the processing step for each FLIM measurement.
An image is taken in CLSM (A), the FLIM software creates an image showing the
various lifetimes and total intensities (B), some of particles are manually circled
in order to remove background noise, these are still colored in image C.
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Table 4.1: Lifetimes of NR668 inside POCA and PBCA particles fresh from the
particle solution measured in solution in various pH buffers.
PBCA POCA
Medium τ1(ns) τ2(ns) τ1(ns) τ2(ns)
pH 7.2 1.4 4.0 1.6 4.1
pH 5.6 1.4 4.0 1.7 4.2
pH 4.0 1.4 4.0 1.7 4.2
process. PC3 cells were incubated with POCA and PBCA particles for 24 hours,
before the medium was changed back to DMEM without any NP. It could there-
fore be assumed that all the particles inside the cells had been endocytosed within
these 24 hours. Particles were also imaged after 5 hours of incubation, and on the
bottom of the sample well immediately after incubation had started. Cells were
also incubated with free NR668 solved in DMSO and diluted in DMEM to gain
reference values and images of free nile red inside cells. Resulting FLIM images
at varying time points are seen in figure 4.20, 4.21 and 4.22. The colors in the
images depicts the average lifetime of each pixel, the color scale running from 2.5
ns to 4 ns. The images reveal that especially for NR668, but also for PBCA par-
ticles, areas of different lifetimes exists inside the cells. To calculate the lifetimes,
6 FLIM images were taken for each particle/dye and time point and ROI’s were
selected. When areas of different lifetimes existed in the same sample, areas of
very long lifetime (red areas) were avoided. Scatter plots of all measurements are
presented in figure 4.23.The corresponding numbers and standard deviations are
found in table C.1 in the appendix part C. In figure 4.24, the average long and
short lifetimes have been calculated for better visualization of the possible trend.
For PBCA, a significant increase for both lifetimes is seen with P-values of 3.5E-5
(short lifetime) and 2.2E-4 (long lifetime) for the difference from the first to the
last time point. For POCA, no clear trend is seen, the P-values from first to last
time point is 0.41 (short lifetime) and 0.53 (long lifetime). The differences seen
for POCA is therefore not significant. It is also worth noticing that for PBCA,
the biggest change occurs between 5h and 24-48h after incubation.
While the images with average lifetimes for each pixel and the exact lifetimes
observed in each case preserves a lot of information for analysis, it is for degrada-
tion purposes also interesting to look at general trends of the lifetimes captured
on various time points. The overall lifetime distribution, where the two lifetimes
have been averaged using formula 2.8, was collected for 5-8 images of each parti-
cle on the different time points to create lifetime distributions. The distribution
of free NR668 is seen in figure 4.25, PBCA in figure 4.26 and POCA in figure
4.27. The distributions show that there is a shift towards shorter lifetimes for
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Table 4.2: A: Lifetimes and standard deviation of NR668 inside POCA and PBCA
particles after 6 days in cell medium, and left in various solutions for 1h prior to
measurement. n=5. B: the P-value from t-test comparing the measured lifetimes
in the different solutions to the lifetimes in DMEM.
A
PBCA POCA
Medium τ1(ns) τ2(ns) τ1(ns) τ2(ns)
DMEM 1.07 (± 0.11) 3.47 (± 0.20) 1.09 (± 0.14) 3.70 (± 0.13)
pH 7.2 1.31 (± 0.08) 3.71 (± 0.11) 1.10 (± 0.15) 3.67 (± 0.08)
pH 5.6 1.09 (± 0.22) 3.51 (± 0.29) 1.04 (± 0.10) 3.62 (± 0.05)
pH 4.0 0.85 (± 0.07) 3.04 (± 0.07) 1.07 (± 0.08) 3.61 (± 0.12)
B
P-value from comparing the lifetime to the lifetime in DMEM
PBCA POCA
Medium Pτ1 Pτ2 Pτ1 Pτ2
pH 7.2 0.004 0.04 0.93 0.56
pH 5.6 0.86 0.76 0.41 0.16
pH 4.0 0.003 0.002 0.77 0.22
NR668 between 5 and 24 hours. For PBCA particles, there is an immediate shift
towards shorter lifetimes from 0 to 5 hours, but from 5 to 48 hours, there is a
large shift towards longer lifetimes that continues on the measurement after 6
days. For POCA NPs, only minor changes are seen.
4.2.2 Spectral analysis
To further analyze the possible intracellular degradation of particles, the emis-
sion spectra from cells with NPs and free NR668 were recorded. The measure-
ments were done scanning for emission spectra, but the adsorption spectra were
first measured to find the optimal excitation wavelength. It was found that
λ = 514nm, the wavelength used for FLIM was suitable (not shown). The spec-
tra were recorded for particles attached to the sample well immediately after
incubation, inside cells after 24 hours of incubation, and inside cells after 6 days.
In the 6th day sample, the cells were incubated with particles for the first 24
hours, the medium was then changed back to DMEM 2 (containing antibiotics)
for the following 5 days. Cells were also incubated with free NR668 after 24 hours
and after 6 days for reference spectra. 5 images were recorded for each sample,
and each image normalized to the same maximum intensity.
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Figure 4.19: Scatter plots showing the average lifetime of NR668 encapsulated in
POCA (A) and PBCA (B) NPs in different pH buffers after being stored 6 days
in DMEM. It can be seen that for PBCA, the lifetime is now depending on the
pH.
Figure 4.28 shows the spectra from PBCA(A) and POCA (B) evolving over
time. It shows that from 0 to 24 hours, the spectra from PBCA particles is red-
shifted, after 6 days it has shifted back towards shorter wavelengths again. For
POCA, the spectra is very similar for all time points except for the shorter wave-
lengths in the first measurement. Figure 4.29 shows the comparison of PBCA,
POCA and NR668 at each time point. Here it is shown that initially(A) the
spectra from POCA and PBCA are similar, while after 24 hours (B) the specter
from PBCA has shifted and is now similar to the specter from NR668 after 24
hours. On the last measurement(C), the spectra is more similar again because
both spectra from NR668 and PBCA has shifted towards shorter wavelengths
making them more similar to the spectra from POCA.
To control that the particles or free dye was still inside the cells after 6 days,
the intensity at the maxima of each spectra was recorded prior to normalization.
The intensities from NR668, PBCA and POCA is presented in figure 4.30. The
intensity is a sum of the pixels in the entire frame and described the amount of
fluorophores in the image rather than the intensity from a single point. It is seen
that for POCA the maximum is reduced to 1/2 while for PBCA, the intensity is
reduced to 1/4. The intensity from NR668 has increased in the same period.
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Figure 4.20: Images showing the lifetime of free NR668 inside PC3 cells after 5h
(A), 24-48 hours(B) and 6-7 days (C). The colors depicts the average lifetime in
each pixel adjusted to the scale attached.
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Figure 4.21: Images showing the lifetime of PBCA particles on the glass slides
after 0h(A) inside PC3 cells after 5h (B), 24-48 hours(C) and 6-7 days (D). The
colors depicts the average lifetime in each pixel adjusted to the scale attached.
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Figure 4.22: Images showing the lifetime of POCA particles on the glass slides
after 0h(A) inside PC3 cells after 5h (B), 24-48 hours(C) and 6-7 days (D). The
colors depicts the average lifetime in each pixel adjusted to the scale attached.
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Figure 4.23: Scatter plots of lifetimes found when PC3 cells were incubated with
POCA (A), PBCA(B) and free NR668(C) for various times.
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Figure 4.24: The average short (A) and long (B) lifetime on the various time
points with standard deviation indicated (n=5).
Figure 4.25: The lifetime distribution of free NR668 at different time points after
incubation, error bars depicts standard deviation based on 5 samples for each
curve. λex = 514nm, error bars = SD, n=5.
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Figure 4.26: The lifetime distribution of PBCA particles at different time points
after incubation, error bars depicts standard deviation based on 5 samples for
each curve. λex = 514nm, error bars = SD, n=5.
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Figure 4.27: The lifetime distribution of POCA particles at different time points
after incubation, error bars depicts standard deviation based on 5 samples for
each curve. λex = 514nm, error bars = SD, n=5.
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Figure 4.28: Emission spectra from PBCA (A) and POCA (B) after 0h, 24h and
6 days of incubation. In the 6 days sample, the medium containing NPs was
removed after 24h. λex = 514nm, Error bars = SD, n=5.
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Figure 4.29: Emission spectra of PBCA, POCA and free NR668 at 0h (A)(PBCA
and POCA), 24h (B) and 6 days(C). In the 6 days sample, the medium containing
NPs was removed after 24h. λex = 514nm, Error bars = SD, n=5.
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Figure 4.30: The intensity at the maximum excitation wavelength of NR668 after
24 hours and 6 days and PBCA and PACA after 0h, 24h and 6 days. Error bars
= SD, n=5.
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4.2.3 Triton treatment
In the preceding sections, it has been presented results describing the state of the
particles based on the state of the fluorophore NR668. A method was sought for
assessing whether the dye was actually fully released from the particle. PC3 cells
were therefore incubated with POCA, PBCA and NR668 for 24 hours in CLSM
imaging wells. While recording the cells 1 image/second with the SP8 confocal
microscope, 15µL of 10% (Tx100) in DMEM was added to the well. The start
point and effect with free NR668 is seen in figure 4.31, PBCA in figure 4.32 and
on POCA in figure 4.33 . The staining is weak and challenging to present on
paper, but it can be seen that the detergent has a different effect on the different
particles and NR668. For NR668, Tx100 induced non specific, diffuse staining of
the cellular compartment. A similar effect was seen with PBCA after 24 hours,
but with slightly less intense staining. For POCA, many distinct points still
remained after adding Tx100, essentially no diffuse staining was observed. The
experiment was also performed after 6 days, with no observed differences to the
results after 24 hours (data not shown).
Figure 4.31: CLSM image of cells incubated with free NR668 for 24 hours before
(A) and after (B) treatment with Tx100
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Figure 4.32: CLSM image of cells incubated with PBCA NPs for 24 hours before
(A) and after (B) treatment with Tx100
Figure 4.33: CLSM image of cells incubated with POCA NPs for 24 hours before
(A) and after (B) treatment with Tx100
Chapter 5
Discussion
5.1 Initial remarks
This thesis describes the mechanisms involved in internalization and intracellular
degradation of POCA and PBCA NPs. It was found that the particles are taken
up through endocytosis and are probably degraded in cytosol, the route indicated
by the results in this thesis is illustrated in figure 5.1. The figure illustrates 5
critical points that were evaluated in this thesis, the state of the NPs prior to
cell contact (1), the uptake mechanism (2 and 3), the intracellular route (4)
and the degradation (5). The discussion chapter has two main parts, cellular
uptake (section 5.2) and intracellular degradation (section 5.3). Part 2 to 4 in
the illustration are described in section 5.2 while 1 and 5 are described in section
5.3. Part 1 has been placed here because the methods used are the same as
in the degradation study and because the results are important for comparison
with the results after degradation. In both these sections, the quality and pitfalls
of the experimental techniques are discussed before the results. In section 5.4,
the overall consequences and impact of these results are discussed and future
directions suggested.
5.2 Cellular uptake
5.2.1 Introduction
In previous work by Sofie Snipstad and Sara Westrøm, it was found that upon
contact with cells, the fluorescent dye Nile red will leak out of the NPs and diffuse
into the cells, eventually settling in intracellular lipid droplets. This made it
impossible to assess the cellular uptake. It is worth mentioning that under CLSM,
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Figure 5.1: Illustration of the route taken by the NPs that was found in this
thesis. Each point (number 1 to 5) shows a point that was evaluated and that is
discussed in this chapter.
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the lipid droplets and NPs have a striking similarity, separating them therefore
calls for other methods than mere imaging. They found that the fluorescence
could be taken up through contact mediated delivery that was not limited by
endocytosis inhibitors nor incubation at 4°C.
This finding made it necessary to reassess the cellular uptake with a sys-
tem where the fluorescent dye is tied to the particle. A collaborator of SINTEF
Materials and Chemistry developed a modified edition of Nile red, NR668 with
essentially the same spectral properties, but being a lot more hydrophobic allow-
ing a stronger binding to the PACA NPs produced[90]. This work was started
by Eva von Haartman, who was a visiting phd student fall 2013. It was then
found that PC3 cells, a human cancer line chosen for this study, had essentially
no uptake of the particles. The first part of the experimental work was therefore
spent on unveiling why such variable degrees of uptake was observed in the first
experiment of this thesis.
The cellular uptake was studied using conventional methods well described
in literature and with significant expertise available in the research group at
NTNU biophysics. The protocols for this part of the project was either found
from previous work, or suggested by colleagues. The master theses by Sara
Westrøm[93] and Sofie Snipstad[80] were frequently used.
5.2.2 Methods used
The uptake of NPs by PC3 cells was evaluated using FCM for quantitative
analysis and CLSM for qualitative analysis. This is a well described method
for evaluation cellular uptake kinetics uses by multiple groups in this field of
research[82][109][110].
FCM offers high throughput analysis of cells, in this study, 10000 cells were
analyzed in each run meaning that the collected population is huge. A question
related to this topic is how to use controls and parallels to verify the different
results. In figure 4.2 the uptake of POCA and PBCA NPs is presented in two
diagrams. In A, the results and standard deviations have been calculated from
3 different experiments, in B, the results are calculated from 3 parallels in the
same experiment. It can be seen that the measured uptake is relatively similar in
A and B, but the standard deviation is far bigger in A. This is not too surprising
given that the results from one measurement is an average of 10000 cells, as long
as the wells in the sample holder are treated similarly, the exact same result can
be expected to occur in two neighboring wells. The standard deviations measured
in the two cases will reflect two different sources of uncertainty. The standard
deviation from parallels in the same experiment originates from instrumental
inaccuracy, while the standard deviation from different experiments reflects the
biological variations.
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For uptake studies, the important reason for doing CLSM is to validate the
results from FCM by observing actually internalized NPs. FCM analysis will
not distinguish between internalized material, and material bound to the plasma
membrane. CLSM can help distinguish between these two scenarios.
A debatable issue is that many of the presented results have been normalized
in some way, both due to prior knowledge and to make related results possible to
compare. In figure 4.2, the actual uptake of POCA has been multiplied by 1/0.52
(see Appendix A) because POCA and PBCA have a different fluorescence. This
could be dubious, or at least an important source of uncertainty to the results.
Fluorescence intensity is not only a question of concentration of fluorescent dye,
but also of the local environment. Nile red for example has a poor quantum
yield in polar solvents and is essentially quenched in water[91]. Binding to low
density lipoprotein, the intensity is more than 10 times higher than when binding
to membranes and 2000 times higher than when bound to defatted albumin.
The dye is highly fluorescent both in lipids and in organic solvents[92]. While
the spectral properties will be throughly examined in section 5.3, the quantum
yield of nile red is important when interpreting the uptake results. The uptake
measured with FCM depends solely on fluorescence intensity. If, during the time
inside cells, the dye is released from the particle and attaches to areas where the
quantum yield or emission spectrum are different, this will affect the results. I
therefore advice that trends and comparisons are emphasized more than exact
values. One must also remember that NR668, the dye in focus, is not identical
to conventional Nile red, the dye described in most of the literature[90].
In the experiment presented in figure 4.10, inhibition of endocytosis, another
interesting normalization issue arises. The goal of that experiment was to asses
the endocytosis mechanism, and the experiment was performed twice. In the
two experiments, very different amount of uptake was seen, but the effect of
inhibitors was exactly the same. When adding these two results together the
experiment showing the highest uptake will dictate the overall result unless some
normalization is done. Also, the different uptake will result in large standard
deviations. This large standard deviation would easily be read as a large vari-
ability in the effect of inhibitors which would be a misassumption because the
deviation seen would mainly be due to the change in absolute uptake of NPs. In
the presented results, the two different experiments have been normalized to the
maximum uptake in order to make the two results contribute equally and the
make the standard deviation represent the actual uncertainty of the inhibition.
The original histograms are found in the appendix part B.
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5.2.3 Cellular uptake
Rate and variability of the cellular uptake of NPs
In order to study the interaction of NPs with cells, it is critical to understand and
quantify the cellular uptake through endocytosis. For the degradation studies, it
is also critical do first document that an actual uptake occurs. Figure 4.1 shows
histograms of cells incubated with POCA and PBCA NPs for 3 and 24 hours
compared to non-treated cells (light blue histogram). The control is needed to
see the level of autofluorescence from the cells. Any increase from this value
will indicate uptake or surface binding of fluorescent dye or fluorescently labelled
NPs. Using CLSM and scanning in Z direction, it was confirmed that the source
of fluorescence was inside the cells, this 3D information is challenging to present
as images, figure 4.3 shows images from the top, center and bottom of the same
cell where the particles are mainly seen in the middle one.
These results show that the particles are taken up by the cells and end up
intracellularly. It was also found that the POCA particles were taken up more
rapidly than PBCA cells, but that after 24 hours, the uptake of PBCA was equal
or higher.
The uptake is relatively slow compared to other studies[110], but well within
the expected range of endocytosis-dependent uptake. The rate of uptake varied
heavily from different experiments. By observing the cells growing in the incuba-
tion flask it was found that the appearance of the cells changed every day from
seeding until confluency was reached. At first the cells were rounded, and seem-
ingly poorly attached to the bottom of the flask, it was therefore hypothesized
that the cells required more time to fully attach than initially expected. It was
found, as seen in figure 4.8 that the uptake depended heavily on days of culturing.
It was seen that the shift in fluorescence intensity tripled if the experiment was
performed 5 days after seeding, rather than 3 days which was initially suggested.
From this result it is natural to hypothesize that the different state of the cells is
the reason for the different uptake seen for POCA and PBCA NPs. However, no
differences in state of the cells in PBCA and POCA sample wells were visually
observed during the experiments.
This information is important to have when quantifying the cellular uptake,
and probably also many other cellular processes. The rate depends on the state of
the cells. Also, this information clearly limits the value of these results as a model
for in vivo properties of this system. It must be expected that in a densely packed
environment in tissue, the magnitude of uptake is different to that observed here.
It was found that the mechanism of uptake was unchanged at different cell den-
sities, indicating that the results on uptake mechanisms and intracellular routing
could work as a model for in vivo properties. Similar observations were not found
in the literature. This could be due to the effect being cell dependent, and more
74 CHAPTER 5. DISCUSSION
important for slowly proliferating cells such as PC3 cells that fewer groups work
with.
It is interesting that the POCA particles are taken up more rapidly than
PBCA particles. These particles are very similar in physical parameters such
as charge and size, and they are pegylated with the same molecules, details are
found in table 3.1. Also, the difference is seen before significant degradation is
expected to occur.
Effect of preincubation
This section explains point 2 in figure 5.1.
An increase in uptake was seen after preincubation with PC3 cells. Figure
4.6 and 4.7 shows the uptake of POCA particles, where the particle solution was
either made fresh, made 21 hours in advance or made 21 hours in advanced and
stored in an incubation flask with PC3 cells. This experiment was only done with
POCA NPs, because after 24 hours, the PBCA particles will be partly degraded.
It was seen that incubating with DMEM for 21 hours had no significant effect on
the uptake, while incubating with PC3 cells for 21 hours increased the uptake by
approximately 50%. This shows that there is no effect of degradation or leaking
from the POCA NP, but that products from the PC3 cells increase the uptake.
This could be proteins produced by the PC3 cells that bind to the particles
and facilitates receptor mediated uptake. Either a protein that the cells secrete
continuously, but most likely the production is triggered by the NP. To further
evaluate these mechanisms would be interesting, but it was beyond the scope of
this thesis. However, understanding this process is important and suggested for
future studies.
Uptake mechanism
This section explains point 3 in figure 5.1.
The NPs are taken up by the PC3 cells through endocytosis. The control at
4°C shows essentially no uptake which means that the uptake is energy dependent.
Inhibiting the two main endocytosis pathways also drastically reduced the uptake,
this is seen in figure 4.10.
It is important that the 4°C cells show no uptake, otherwise, one would expect
that the particles are still leaking fluorescent dye. For example in Sofie Snipstads
master thesis, she found only a very limited reduction of uptake at 4°C [80]. At
4°C, the cells are unable to perform energy dependent processes. Some papers
see only partly inhibition at 4 °C, which implies that also energy independent
processes such as diffusion takes place[111][112][113]. It is not rare that only
limited inhibition is seen at 4 °C, but full inhibition is also reported[114].
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Inhibition of CME was done using Chlorpromazine with a protocol used by
others studying endocytosis in PC3 cells[107]. Figure 4.10 shows that the uptake
of both POCA and PBCA particles are reduced to approximately 50%. Chlor-
promazine works by inhibiting a GTPase involved in formation of clathrin coated
pits[71] and is reported to be very selective for CME, but not function properly
in some cells[61].
Inhibition of caveolin-mediated endocytosis was done using a protocol for
Genistein that had been shown effective for PC3 cells[108]. It was found that
the uptake of PBCA particles was not inhibited by Genistein indicating that
caveolin-mediated endocytosis is not an important mechanism for internalization
of PBCA particles in PC3 cells. For POCA, Genistein had a significant effect
reducing the uptake to 52%. This suggests that for POCA particles, clathrin-
and caveolin-mediated endocytosis contributes equally to the uptake and that
the entire uptake of POCA can be accounted for with these two mechanisms.
Genistein is less selective than Chlorpromazin, and could possibly inhibit also
other mechanisms than caveolin-mediated endocytosis[61]. Both tyrosine kinase
and F-actin is blocked, which means that CME could also be inhibited either if
tyrosine kinase receptors are involved[72], or if F-actin is blocked from the clathrin
coated pits[115]. It is therefore possible that other mechanisms than caveolin-
mediated endocytosis might be the reason for the different effect of Genistein on
the uptake of POCA and PBCA.
While the exact mechanism inhibited by Genistein remains disputed, the re-
sults reveal that the POCA and PBCA particles are not as similar as the physical
data and production method might suggest. These two particles are made using
the same chemistry, where only the alkyl group on the monomer is different. Ide-
ally though, the particles should be covered with a dense layer of PEG, making
the core material invisible to the cells. There are two parameters that seem most
likely the source of this difference, size and surface. From table 3.1 it is seen that
the POCA particles have a diameter of 151 nm, PBCA 177 nm. The diameter is
measured immediately after dilution from the particle solution and with dynamic
light scattering (DLS), reporting the hydrodynamic diameter. However, it was
found by Andreas Bøe[7] that in a buffer of pH of 7, the PBCA would swell by
more than 25% within the first 10 hours while for POCA the swelling was limited
to less than 5%. This means that the actual size difference seen by the cells might
be bigger, and that the diameter of PBCA will exceed 200nm making the size
difference between the two particles around 50nm within hours after dilution. In
the experiments, the particle dilution was done within one hour prior to start of
incubation. It has been documented that size is an important parameter for the
amount of uptake. Rejman et al.[63] found that increasing the particle size from
50 to 100 nm would reduce the uptake 3-4 fold while increasing the size from 200
to 500nm would reduce the uptake 8-10 times. They also saw that the smaller
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particles could be detected immediately after incubation while the particles at
500 nm were only detected in significant amounts after 2-3 hours. Interestingly,
this same group also saw that CME had an upper size limit of approximately
200nm in the melanoma cell line studied. Larger particles (mainly 500nm) were
internalized by a caveloae-dependent pathway. This is not caveloin-mediated
endocytosis as originally described though, the flask shaped caveolin has been re-
ported to be smaller than 100nm and often closer to 50nm[116][66]. In this study,
the smaller particles (POCA) showed a connection to caveloae endocytosis, while
for the larger, no such connection was found. Still, being far from the 500nm size
studied, the cut off at 200nm is more relevant to this study. It is not unlikely
that at least some of the differences seen is a result of the different size of the
NPs.
Another option is that the surfaces of POCA and PBCA in reality are differ-
ent and binds biological molecules with a different affinity. The particles are both
pegylated using the same surfactants BRIJ 35 and Jeffamin. Also, the measured
zeta potential is very similar (table 3.1) and recent results from nuclear magnetic
resonance spectroscopy indicates that the amount of PEG on the NPs is essen-
tially the same. The potential difference is then likely to be the homogeneity of
the pegylated surface. Although there are many ways of measuring the amount
of PEG, non of them are straightforward nor will they tell you the exact density
of surface bound molecules[117]. The effect of PEG on the PBCA particles in
this thesis was described in previous work[8], where it was found that the pe-
gylation was important to avoid aggregation in certain media, but not sufficient
to fully avoid the formation of a protein corona in protein-containing solutions.
It has been shown that increasing the amount of PEG can decrease the uptake
by cells especially particles that do not target specific receptors[114][118]. and
that for PACA NPs the phagocytic uptake is decreased 10-fold with sufficient
pegylation[110].
It was found that incubation the NPs with PC3 cells for 21 hours prior to the
uptake study would increase the uptake significantly. This could indicate that
the cells produce a protein that attaches to the particles and allows for receptor-
mediated uptake. This secreted protein could have different affinity for the two
particles. Given that the amount of PEG is the same, it is likely the monomer,
BCA or OCA that lead to the difference in affinity something which indicates that
the particles are not sufficiently pegylated. Interestingly, in rat brain endothelial
(RBE4) cells that are being studied by a colleague (unpublished results), the
uptake of PBCA is higher than for POCA, and it was found that PBCA is taken
up through both clathrin and caveloin mediated endocytosis while POCA was
only taken up through the clathrin-pathway. These results are opposite of those
observed for the PC3 cells in this thesis. This observation can be explained by the
different cells secreting different proteins that have affinity for different surfaces,
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which is interesting because brain endothelial cells which constitute the blood
brain barrier are known to specifically endocytose PBCA NPs[119][120]. These
results implies that secreted proteins might be the reason for this affinity.
If differences in pegylation is the reason behind the different uptake of POCA
and PBCA, heterogeneity in the pegylation is likely the reason which implies
that POCA is more heterogeneously pegylated than PBCA. POCA is the particle
that was shown to be endocytosed through caveolin-mediated endocytosis. One
could therefore argue that the difference seen is due to POCA being compatible
with caveolin-mediated endocytosis while PBCA could be incompatible with this
endocytosis mechanism. A closer look at the numbers however will show that
even the amount of POCA uptake inhibited by Chlorpromazine is bigger than
the total uptake of PBCA, showing that the different magnitude of uptake is not
solely due to caveolin mediated uptake of POCA NPs.
Caveolin is used to internalize membrane lipid rafts, mobile areas in the
plasma membranes densely packed with lipids such as cholesterol[116][121]. These
lipid-rich areas are more hydrophobic, and might show some affinity towards hy-
drophobic, poorly pegylated areas of the NP. For the internalization of these lipid
rafts, the tyrosine kinases inhibited by Genistein are important[61]. One could
hypothesize that POCA NPs attach to lipid rafts and are endocytosed through
a tyrosine kinase dependent mechanism.
This theory is far more speculative than the explanation based on particle
size or protein affinity, but it can not be ruled out that heterogeneous pegylation
is involved in the uptake difference.
After 24hours, the uptake of PBCA has reached that of POCA in terms of
mean fluorescence intensity from the cells. To draw conclusions based on this
information is challenging because at 24 hours, parameters such as degradability
of the particles and properties of the fluorescent dye comes into play. However,
the results are quite striking, after 3 hours, POCA is endocytosed 3-10 times more
than PBCA, while at 24 hours, the uptake is similar. The possible explanations
to this observation can be grouped in two. Either the PBCA particles are actually
taken up more effectively than POCA after some hours, or the result is due to
an artifact possibly created by the fluorescent dye.
The PBCA particles will be partly degraded after 24 hours, this means that
the particle will release hydrophobic dye, and some of this increased uptake might
be due to this effect, the control at 4°C also showed a minor uptake of NR668
for the sample with PBCA particles. The degradation is limited though, in
Bøes master thesis[7], it was found that the PBCA particles were a lot more
stable in cell medium than in a pH 7.4 buffer. It is not unrealistic though to
expect increased uptake as the particles are becoming slightly degraded and less
pegylated. It is likely that the increased uptake of PBCA seen with time is due to
degradation and internalization of either degraded particles or released NR668.
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It is also possible that the measured high uptake of PBCA after 24 hours is an
artifact caused by the interaction between the particle, cell and the hydrophobic
dye NR668. From the results presented in this thesis and in work by Andreas
Bøe[7] one can assume that the PBCA particles are, at least to some degree, de-
graded after 24 hours intracellularly. This will release fluorescent dye an allow it
to diffuse to other locations. NR668 is a very hydrophobic molecule and will if de-
graded from the particle, diffuse to other hydrophobic regions such as intracellular
lipid droplets. Nile red was originally developed as a stain for these droplets[91].
In the original paper describing NR668, they found that auto-quenching occurs
if the dye is too concentrated. In 40nm oil droplets, Klymchenko et al.[90] found
that 5%wt. of NR668 in the droplet would have a quantum yield of 13%, while
1%wt. NR668 had a quantum yield of 60%. This lead to somehow surprising
result that the particle can be equally fluorescent even if 4/5 of the dye has leaked
out. However, spectral measurements presented in figure 4.28A do not show the
blue-shift that would be expected with increased quantum yield. Also, the the-
oretical amount of NR668 in the particle is only approximately 0.2%, far below
the concentrations used in the referred article. There is no guarantee though,
that the dye is uniformly distributed in the NP and that higher concentrations
can not be found locally.
Intracellular routing
This section explains part 4 in figure 5.1.
Colocalization with lysosomes was found, less so for early endosomes. Uptake
through endocytosis should lead to the particles being routed through early en-
dosomes, late endosomes and lysosomes[122], colocalization with these organelles
would therefore be expected. Figure 4.11 and 4.12 shows PC3 cells transfected
with Cell Light GFP transfection agent for staining early endosomes. It was
found that transfected cells had a high expression of GFP making colocalization
difficult. This is probably due to deficient staining protocol and could be im-
proved in future studies. In figure 4.12, the intensity has been reduced, making
only the brightest areas visible, a possible colocalization is seen under the white
arrow. Early endosomes has a very short lifetime and will normally become a late
endosomes within 10 minutes after internalization[75]. Although some colocal-
ization with early endosomes would be expected, it is not too surprising that this
is difficult to observe given the slow rate of uptake and the limited time spent on
perfecting the staining protocol.
The particles were found to colocalize with lysosomes. Figure 4.13 shows a
PC3 cell incubated with POCA NPs for 24 hours and stained for lysosomes. In
the image, pixels will be colored yellow if roughly equal intensity is detected in the
two channels. The image shows that many particles are found inside lysosomes,
but also that many particles were found to not be inside lysosomes at this time
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point. The colocalized lysosomes and NPs were found in close proximity of the
cell nucleus. The image is consistent with images taken by other groups who
have looked for colocalization with lysosomes and NPs[123][61][124], where the
lysosomes are also found in proximity of the nuclei.
Finding the NPs colocalized with lysosomes verify that that the particles are
going through endocytotic uptake and intracellular routing. It is interesting how-
ever, that these particles do not seem to remain in the lysosome. The degradation
studies showed a rate of degradation for the PBCA particle that is much more
rapid than what would be expected if the particle remained in lysosomes. Also, in
image 4.13, only a fraction of the NPs are colocalized with lysosomes. The mech-
anism for lysosomal escape is not understood nor described in the literature[77],
but should be the goal of future studies.
5.3 Intracellular degradation
5.3.1 Introduction
In previous work, Andreas Bøe evaluated the degradation by measuring decrease
in the particle concentration in different solutions and at various time points
using Nanosight[7]. He found that the POCA NPs were essentially stable under
a biological relevant range of pH, but some degradation was seen at pH 7.4 in
combination with esterase. The PBCA particles were stable at pH 4, relatively
stable in cell medium and pH 5.6, but would degrade quite rapidly at pH 7.4
with a half life of less than 24 hours. No effect of esterase was seen for the PBCA
particles. He also found that the particles would increase in size in cell medium,
likely due to swelling, and that this occurred more for PBCA than POCA. In the
study and discussion of intracellular degradation, his results are highly relevant.
For measuring intracellular degradation of NPs, no established method was
available. In the literature, Fo¨rster resonance energy transfer (FRET) is often
presented as the golden standard for detecting degradation. For this technique,
two dyes with a suitable excitation and emission spectra must be in close proxim-
ity to get a FRET signal indicating that the particle is still intact[125]. Unfortu-
nately, the PACA particles produced at SINTEF are very sensitive to properties
of the load and loading two dyes functioning as a FRET-pair to the same particle
has not yet been accomplished. A lot of effort was therefore put in to exploiting
properties of NR668 to detect changes in the local environment of the fluores-
cent dye and to draw some conclusions based on that information. However,
NR668 being a new dye, no literature is available as reference. Therefore articles
describing conventional nile red are used, but with great care as reference and
comparison to understand the observed results.
80 CHAPTER 5. DISCUSSION
5.3.2 Methods used
Finding unambiguous signs of the intracellular degradation of the NPs was diffi-
cult and conclusion are based on results from multiple techniques which all gave
some clues, but neither offered the full solution. In the literature, similar systems
have been evaluated using self-quenching[126], FRET[127], and often the degra-
dation is measured in solutions and assumed to be the same intracellularly[128].
These systems were either not available or desirable in this situation, and other
methods were sought. Snipstad[80] had shown that free nile red would appear
both as bright spots and diffuse staining inside cells, this could be easily ob-
served. Greenspan et al.[91] have described the spectral footprint of Nile red
and a method for spectral separation of nile red in lipid droplets and diffuse nile
red in cytosol. However, this diffuse staining was never observed nor imaged for
NR668 except when artificially induced by adding detergent to the cells (sec-
tion 4.2.3). The main property of NR668 compared to nile red is the increased
hydrophobicity[90]. It is likely that this increase limits the amount of nile red
binding to proteins in cytosol because NR668 has a stronger attraction towards
the lipid droplets. Intracellular free NR668 was visually similar to POCA or
PBCA particles, imaging did therefore not offer any knowledge of the intracellu-
lar degradation.
FLIM
The fluorescence lifetime of the fluorescent dye is a property related but not
similar to the emission spectrum. If a suitable dye is found, FLIM is described
as a potentially ideal tool to observe intracellular processes because the lifetime
depends on excited state reactions, but is independent of fluorophore concentra-
tion and light-path length[129]. For nile red, a selection of properties have been
explored for lifetime measurements such as elastic modulus of the encapsulation
material [89], solvent polarity[95], hydrogen bonding strength[130] and concen-
tration of cholesterol[131] in the local environment. To my knowledge, no studies
on the lifetime properties of NR668 are published.
From the referred literature and from experience during the work in this thesis,
it is found that the fluorescence lifetime of the excited state of NR668/Nile red is
very sensitive to the surrounding environment. This, and the lack of comparable
studies made it challenging to interpret the results. The number of variables
inside the cell is vast, and the intracellular behavior and location of the NP and
NR668 is not fully characterized. The results from FLIM did offer some clear
trends that could support conclusions, but also results opening up for discussion
and further investigation. Given the limited time available, further investigations
had to be postponed to future studies. One concrete case that could be studied
in the future is the possibility to find a distinct lifetime of NR668 in lysosomes
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by measuring the lifetime of spots colocalized with labelled lysosomes. A theory
would be that NR668 has a clear signature from inside a lysosome given the low
pH[132], it was found that for degraded/slightly degraded particles, the pH would
have a significant effect on the measured lifetime (figure 4.19 and table 4.2). A
drawback of FLIM is that it might be too sensitive for some applications and for
doing quick and easy measurements. Some variability within the results from each
sample was found (table 4.2), this makes it necessary to do multiple measurements
for each sample if one wants to record and compare lifetimes numerically. Each
measurement is also time consuming and requires manually selecting suitable
ROIs. Also, some work was required to find suitable imaging conditions that
minimized the noise and reflections from the sample holder (figure 4.16).
It was found that NR668 holds a great potential for monitoring intracellular
processes. If cause and effect of various parameters are further analyzed, NR668
could provide information on state of the particles and possibly colocalization
with endocytic vesicles.
It was not clear how to best present the results from FLIM. Figure 4.23 show
scatter plots of exact lifetimes, while 4.25, 4.26 and 4.27 shows the distribution
of lifetimes in the same images. The images in figure 4.20, 4.21 and 4.22 resemble
fluorescence microscopy images, but each pixel has been given a color related
to the average lifetime in that pixel. Although calculated from the same set of
images, these different ways of presenting and reading the data each holds some
specific information.
Spectral analysis
The measurement of lifetimes and spectral analysis of particles outside cells was
done in the proximity of the sample well. It is important to be aware that this
imaging condition is suboptimal and different from the images and measurements
of particles inside cells. An example of this is the emission spectra presented in
figure 4.28. It can be seen in the measurements on the first time point, high
intensity is seen in the blue(short wavelength) side of the spectra. This intensity
could possibly be due to the scattering from the glass. The excitation laser at
514nm is relatively close to the detector range of FLIM (565-615 nm) and the
lowest detected wavelengths in spectral analysis (530 nm) and could therefore
lead to detected light that is scattered from the glass and not emitted by the
fluorophores.
The reason for doing spectral analysis was to confirm the observations from the
FLIM measurements. Compared to FLIM, spectral analysis has the advantage
of being fast and well described in the literature. It was also found that the
emission specter is less sensitive to the environment than FLIM making it easier
to separate noise and randomness from true differences. This is seen as a generally
lower standard deviation in the results from spectral analysis than in the results
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from FLIM. A major drawback of spectral analysis is that it is depending on
fluorophore concentration, adding a variable that is difficult to control to the
equation.
Triton
Triton is a detergent that will solve lipids and lipid membranes. The reason
for using it in this thesis was to see if some red dots would be dissolved (lipid
droplets) and others would remain (intact NP) upon addition of Triton. The idea
came from an article by Bjørkøy et al.[133].
It was found that the experiment had a low reproducibility, the magnitude
of the effect was different from time to time. Sometimes the cell in focus would
immediately disrupt and all fluorescence stain leak out to the environment, and
sometimes hardly any effect was seen. Separating lipid droplets from intact NP
was therefore difficult due to this. However, in cases were the effect was relatively
low, a diffuse staining of the cell would occur within 45 seconds after addition of
Triton. This was observed for free NR668 and PBCA, but not for POCA.
5.3.3 Degradation
Nanoparticles before cell contact
This section explains point 1 in figure 5.1.
FLIM images suggest that especially the PBCA particles are not all fully
polymerized towards the core of the particle, this is seen in figure 4.17. This has
not been documented previously, but transmission electron microscope (TEM)
images taken in an ongoing study indicate the same (unpublished results). With
both imaging systems (TEM and FLIM), this is especially evident for the larger
particles. With FLIM, it was found that with fresh particles, the lifetime did not
depend on the pH in the solution (table 4.1) while after 6 days in cell medium
(table 4.2) the lifetime from PBCA particles varied significantly with pH. No
change was found for the POCA particles. The lifetime in PBCA was found to
be shorter with low pH ranging from 0.85/3.04 at pH 4 to 1.31/3.71 at pH 7.2
(short lifetime/long lifetime). It has previously been documented that the PBCA
particles are relatively stable in cell medium with more than 2/3 of the particles
left after 4 days incubation[7].
The result of pH variations could support the theory that the particles have a
liquid or poorly polymerized core. It is hard to imagine the fluorophores encapsu-
lated within a solid NP changing with the pH because the fluorophore is protected
inside the particle. For the POCA particles, very little change in lifetime was ob-
served intracellularly although many of the NPs were found to colocalize with
lysosomes. Also, when the particles are imaged directly after being mixed with
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cell medium, no effect was seen. This indicates that the lifetimes presented for
PBCA NPs in table 4.2 are not intact NPs. Here it was found that the lifetimes
varied significantly with pH in the buffer solution. The NPs are attaching to the
sample well more readily after 6 days than immediately after mixing. Especially
at low pH, no particles were found on the sample well from freshly made particle
solutions. This suggests that the particles have become less pegylated during the
time in DMEM and the same effect was observed for both POCA and PBCA
particles. The lifetime from POCA NPs however does not depend on pH, and
the particles are therefore still solid. For PBCA, the result suggests that the
material stuck to the sample well is not solid NPs, but might be degraded or
slightly degraded polymer material in an oil droplet.
The initial lifetime from NR668 in POCA and PBCA NPs is different due
to either different elastic modulus of PBCA and POCA or due to different hy-
drophobicity. It has been established that the fluorescence lifetime in polymer
material is highly dependent on the modulus of elasticity[89]. POCA is a harder
material than PBCA and a longer initial lifetime was found (table 4.1). With
the limited amount of literature available for comparison, it is an important con-
firmation of the technique that the finding is in compliance with one of the few
available references[89]. The numerical values match the expected values from
similar materials examined in the referred article, if one consider the expected
value for solid particles rather than particles with a liquid core. An important
source of error that comes into play here is that the population of particles stuck
to the sample holder might not fully mirror the complete population of parti-
cles. If the imaged particles are bigger and poorly polymerized, this might also
affect the pegylation and stability in solution. This result lead to the conclusion
that the initial measurement of particles at 0h should be handled with some care.
This also suggests that a liquid core might not be an important property for most
particles in the solution.
The most important conclusion from this experiment is that the information
obtained at 0h for both lifetime measurements and spectral analysis is not from
intact particles and should be handled with care. For example in figure 4.26,
where the distribution of lifetimes from PBCA NPs at different time points is seen,
the distribution from 0 hours does not fall into the trend seen at the other time
points. This could be because the 0h measurement is done on the subpopulation
of particles that stick to the sample well that are poorly polymerized and degrades
faster.
Intracellular degradation
This section explains point 5 in figure 5.1.
It was found that the PBCA NPs degrade significantly during 24 hours intra-
cellularly while the POCA particles remain essentially unchanged. This rate of
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degradation is in compliance with previous work[7].
This is not as obvious as it might seem. In lysosomes the pH is close to 4[25]
and it has been documented that both these particles are highly stable at this
pH. In endocytosis, the internalized material is normally degraded in lysosomes,
where enzymes and low pH is effective to most biological material[134]. Different
pathways can be taken from the lysosomes, but degraded material is often released
in cytosol, or trafficked out of the cell through autophagy/exocytosis[25]. The
PACA particles are poorly degraded in the lysosomes, this could make exocytosis
a likely outcome. It has been observed by others that NPs that are covered in
albumin from cell medium is rapidly cleared by exocytosis[135]. For the drug
delivery, this is a challenge. The goal is to create particles that can release the
drug inside cells in a controllable manner. Exocytosis or continuous habitation
of lysosomes would be devastating to the potential of these NPs as platforms
for drug delivery. In this thesis it is shown that the NPs are still inside the
cell after 7 days. It is also shown only partly colocalization with lysosomes, and
a degradation rate incompatible with storage in lysosomes has been found for
the PBCA particles. Together, this is a clear sign that the particles are able
to escape the lysosomes and degrade in cytosol. If this is the case, this is an
important discovery making the particles very promising for drug delivery.
Figure 4.15 shows the first attempt to observe intracellular degradation after
24 hours. It can be seen that the distribution of free NR668, PBCA and POCA
NPs are visually very similar inside the cell. Conventional nile red is a stain for
lipid droplets and NR668 is even more hydrophobic which makes it very unlikely
to observe the dye bound to a protein or membrane. Lipid droplets/lipid bodies
are intracellular storages of fat with a size ranging down to 100nm[136].
The degradation was documented using FLIM, spectral analysis and cell lysis
with Triton. The images in figure 4.20, 4.21 and 4.22 shows the distribution of
average lifetimes from 2.5 ns to 4 ns inside cells that have been incubated with
NPs or free NR668 for various times. The images show that for free NR668,
defined areas of different colors are visible after only 5 hours and very distinct
after 24-48h. For PBCA NPs, the same tendency can be seen after 24-48 hours,
and after 6-7 days also areas of lifetimes close to 4 have started occurring. For
POCA NPs, even after 6-7 days, the lifetimes is essentially the same ranging
only between yellow and faint green. Intuitively, this result suggest that PBCA
NPs will eventually express the same distribution of lifetimes as free NR668,
suggesting that the dye inside the particle has been released to the surroundings.
To get more quantitative knowledge, ROI’s were selected in each image, and
the decay was approximated to a two exponential decay. The two-exponential
decay was used because of the observation that single-exponential decay gave a
large residual and based on existing literature[89]. The lifetimes that were found
are seen in figure 4.23. Of the three dot plots, 4.23 B, showing the lifetime from
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cells with PBCA particles is the only one suggesting a clear trend. Through the
four time points, it can be seen that the lifetimes are continuously increasing.
Also, they are grouped with the lifetimes after 0h and 5h in the lower left corner
and the lifetimes from the two later time points located close together in the upper
right part of the diagram. This is highlighted in figure 4.24 where the trend of
the average short (A) and long (B) lifetimes are seen. In Bøes master thesis [7],
it was found that after 48 hours the PBCA particles would be highly degraded
unless stored at low pH. The results here also indicate that the main difference
is seen in the time from 5h post incubation until 48 h post incubation. In figure
4.24 it is seen that the lifetimes of NR668 are reduced through the measurements,
the reason for this is not clear, but is is possible that with time NR668 will diffuse
to areas of increasing hydrophobicity resulting in shorter lifetimes.
Figure 4.23 A and C shows the lifetimes of POCA NPs and free NR668.
Especially for POCA particles, no trend is seen. This indicates that very little
happen to the particles within the first 7 days of incubation. This was also seen
measuring the effect of pH outside cells (figure 4.19).
It is a challenging task to understand and explain why the lifetimes change the
way they do. The literature offers very few general guidelines for interpreting,
and changing one condition can have an opposite effect on the lifetime of two
different dyes. Also, one can not be certain that what is found for Nile Red is
also valid for NR668, the original article describing NR668[90], report different
excitation and emission maxima of Nile red and NR668 in various solutions.
To help interpret the results, the emission spectra on the various time points
are valuable. The spectral properties of NR668 has been found to depend on con-
centration and polarity/hydrophobicity while the effect of pH and material elas-
ticity is not described[90]. In figure 4.28, the spectra of PBCA(A) and POCA(B)
are presented. It can be seen that there is a clear red-shift in the emission spec-
tra from PBCA, while the emission spectra from POCA is very similar on the
three time points. The high intensity seen in the shorter wavelengths on the mea-
surement at 0 hours could possibly be an artifact from measuring on the glass
as discussed in the previous section. Figure 4.29 compares the emission spectra
from PBCA and POCA at 0h (A), and the emission spectra of PBCA, POCA
and free NR668 after 24 hours (B) and 6 days (C). It is seen that the spectra of
PBCA and POCA are very similar on the measurement after 0h. This is an im-
portant validation of the method. When neither particles are degraded, the local
hydrophobicity and concentration are relatively similar, and the spectra should
hence be the same. This also indicates that different variables are important for
the fluorescence lifetime and the emission spectra because the initial lifetimes of
PBCA and POCA are not similar. In 4.29 B, it can be seen that within the first
24hours, the spectra from PBCA has changed and is now similar to the spectra of
free NR668 after 24 hours intracellularly. Surprisingly, after 6 days, a significant
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blue shift is observed both for PBCA and free NR668 making them more similar
to the emission spectra of POCA. This is probably due to the dye diffusing to
more hydrophobic domains.
The maximum intensity from the emission spectra was also recorded. Figure
4.30 shows that the average intensity over 5 images is reduced for POCA and
PBCA from 24 hours to 6 days, while the intensity from free NR668 is main-
tained at the same level. The reduction in POCA particles is reduced to roughly
50% while PBCA is reduced to 25%. The most important reason for this shift is
that the cells have undergone multiple cell cycles within these days without NPs
in the solutions. This means that the particles that were encapsulated by one cell
after 24 hours will after 6 days have been distributed to multiple daughter cells.
The difference between POCA or PBCA could indicate one of two things. Either
POCA has a more toxic effect than PBCA, reducing the rate of cell proliferation,
or the intensity of PBCA is reduced because in these samples, NR668 has dif-
fused to less hydrophobic domains where the quantum yield is lower or has been
removed from the cell. The first option is improbable because the medium con-
taining NPs is removed after 24 hours, meaning that the amount of NPs per cell
decreases from this point. The second option is in compliance with other results
in this thesis showing that the particle is degraded. It is not clear why intensity
has not been decreased for free NR668, it is possible that the concentration of
free Nile red in the solution is above the maximum that can be solved in the lipid
droplets and that significant amounts of quenched NR668 are also present in the
cells.
Lysing the cells with Triton was only partly successful because the effect
varied from experiment to experiment. The observations from those experiments
are difficult to present on paper, but the attempt is presented in figure 4.31, 4.32
and 4.33. It was seen that upon addition of Triton a faint staining of the entire
cell, except the nuclei, was observed both for free NR668 and PBCA, but not for
POCA. This is interpreted as the detergent making the lipid droplets solvable
in the intracellular compartment, intact NPs however would not be affected by
addition of the detergent.
Comparing the results from FLIM and from emission specter analysis it is pos-
sible to conclude on the degradation of the NPs. For POCA particles, the general
trend is that the change with time is insignificant. This is also in compliance with
the FLIM images in figure 4.22, where a narrow distribution of lifetimes is seen
compared to free NR668 and PBCA. Adding Triton to the cells incubated with
POCA particles also support the conclusion that the intracellular degradation of
POCA particles is very limited after 6 days.
The lifetime measured from PBCA particles increases with time over the four
measurements and it can be considered very likely that these particles are either
degraded or has delivered a significant amount of free NR668 to the cell. Both
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from FLIM and spectral analysis, the initial values measured for the PBCA NP
are different for the endpoints, and the lifetimes are also different to those found
for free NR668, which is also an important piece of information. If the fluorescent
dye was released from the particle, without the particle degrading, one should
expect to find lifetimes identical to those found in cells incubated with free dye
only. The scatter plots in figure 4.23 show that the longer lifetimes measured in
cells incubated with PBCA particles is higher than the lifetimes found for free
NR668, this suggests that the remaining material from the particle still plays a
role. This is not surprising though, BCA is a highly hydrophobic molecule and
once degraded from the particle is likely to end up in hydrophobic domains along
with the fluorescent dye. FLIM, being highly sensitive to the local environment
can be expected to react to this.
The red-shift seen in the emission spectra from PBCA particles is likely to
result from NR668 occupying less hydrophobic domains than the particle. This
effect is well documented in the literature[90][91]. When the particle is degraded
and NR668 is released to the surroundings, NR668 will bind to hydrophobic areas.
If the molecules here have a higher polarity than the polymer, the emission spectra
will be red shifted as seen in figure 4.29A. The quantum yield will also decrease,
suggesting that the magnitude of released dye could actually be bigger than what
is seen in the result. The slight blue-shift seen from 24 hours to 6 days in the same
figure can occur because the degraded monomer and free NR668 will slowly be
drawn towards the most hydrophobic domains, creating lipid droplets consisting
of both particle residuals and NR668 in an environment not too different from
that of the intact particle. This means that after 24 hours intracellularly, many of
the red dots seen in CLSM images is in reality lipid droplets stained with NR668
that has been released from the PBCA particles.
5.4 Concluding remarks
Throughout this thesis, the uptake in PC3 cells and intracellular degradation of
POCA and PBCA particles has been evaluated. PACA NPs for drug delivery
is promising amongst other due to the controllable degradability, this has been
stated in numerous research articles and reviews[137][138][139][140]. To assess
the overall potential of the particles evaluated in this thesis, a quick review of the
necessary properties of a drug carrier is needed. The NP must be biodegradable
to reduce toxic effects and accumulation in healthy tissue. The particles must
either be small enough to exploit the EPR-effect, exploit active targeting or be
subject to external stimuli. At the same time the particle must be large enough
to carry the drug load. The rate of degradation should allow the particles to be
within the tumor or ideally inside the tumor cells before the drug is delivered,
but at the same time the particle must degrade fast enough to allow a sufficient
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local concentration of released drug.
The particles in this thesis are made from either PBCA or POCA, both ma-
terials that have previously been shown to be relatively biocompatible[141][142],
and the effect of the particle pegylation was assessed in previous work[8]. Mech-
anisms for targeting the tumor is currently being developed by my colleagues,
(mainly unpublished data). Within the research group related to this project,
the EPR effect, focused ultrasound, focused ultrasound and microbubbles, active
targeting with RGD and eﬄux pump inhibition are all being tested or developed
for use with these particles[21][5][143]. The goal of this thesis was to evaluate the
mechanisms after the particles have reached the tumor.
It was found that both PBCA and POCA particles are taken up in PC3
cells by endocytosis. The uptake of POCA was found to be higher in the short
term, with 4-10 times higher uptake than PBCA after 3 hours. It was found
that both clathrin- and caveolin-mediated uptake were important for the uptake
of POCA, while PBCA is insensitive to selectively inhibiting caveolin-mediated
endocytosis. This difference can explain some of the differences in uptake. The
reason for this difference is not fully identified, but it has previously been found
that the PBCA particles in cell medium quickly swell to a diameter well above
200 nm, and this might lead to the slower uptake of this particle. Also the
amount and homogeneity of PEG should be evaluated as a possible explanation
for the slightly deviating uptake of POCA and PBCA NPs. Importantly, it
was found beyond any reasonable doubt that particles were internalized, and
not free dye as seen in previous studies. This shows that the chemistry for
encapsulating hydrophobic molecules is functional and that the particles can be
used for degradation dependent drug delivery. Also, documented endocytosis is
vital for the analysis of the intracellular degradation.
Inside the cell, the PBCA particle is degraded and the drug released in cytosol.
The result in this thesis and knowledge of the degradation at lysosomal pH makes
it possible to conclude that the particles do not remain in lysosomes. Results
both from FLIM, spectral analysis and Triton experiments show that after 24
hours intracellularly, a large part of the fluorescence molecules are in a similar
environment as free NR668. This shows that the fluorescent dye is no longer
within the particle, but released and diffused to liquid droplets in cytosol. This
study also show that after 6 days, a significant part of the remaining particles
and free NR668 is still inside the cell showing that if exocytosis occurs, it is
to a very limited degree. This rate of degradation and delivery is well suited,
and possibly faster than extracellular degradation. Although Bøe in his Master
thesis found that the PBCA particles had a half life of less than 24 hours, the
same was not the case for particles at lower pH or in cell medium. As described
in the theory section, tumors often have a lower pH than healthy tissue due to
anaerobe energy consumption[26]. Release of drug will therefore be postponed
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until the particles are internalized. The particle will protect healthy tissue from
the effects of the cytotoxic drug until the particle has either reached its target or
been removed from circulation by the RES system. It has been found in related
systems, that even with extensive pegylation, less than 30% of the particles are
found circulating after 4 hours[144]. For the PBCA particles in this thesis it was
found that after 5 hours, the lifetime from PBCA is still more similar to the initial
lifetime than the lifetime of free NR668. From the results in this thesis PBCA
NPs can be regarded a promising platform for drug delivery.
POCA particles are much less degraded, and is in those terms less promising
for drug delivery. Still, there are potential applications for these particles as well.
First of all, it shows that using PACA chemistry, it is possible to create also
stable particles. It is possible to mix OCA and BCA to create new particles, and
the POCA particles represent the lower boundary in terms of degradation rate
for this family of NPs[48]. One could imagine creating a cancer therapy protocol
where particles of different variations of POCA and PBCA are used to create a
continuous release of drug that lasts for weeks. This could be favorable because
many cancer drugs target specific step in the cell cycle, and is only functional
towards actively proliferating cells[15]. Temporary quiescent cancer cells will not
be affected by most of the drugs available. Another potential application for the
POCA particles is for imaging purposes, where you want to monitor the location
of the particle.
5.4.1 Future directions
This thesis follows two years of projects and master theses that have been focused
on PACA NPs encapsulating a fluorescent dye as a model drug. It has now
been documented that hydrophobic drugs can be delivered intracellularly, either
through contact mediated delivery[80] or through endocytosis and intracellular
degradation. What remains unknown is the intracellular distribution and effect
of the delivered drug. It would therefore be suggested that future studies revolves
around NPs encapsulating a true drug. This way it is possible to assess whether
the drug loading capabilities and rate of degradation is sufficient to have an
impact on treatment of cancer.
There are also some loose ends from this work that should be subject to con-
tinuous study. The uptake mechanism was not completely described, and it was
not fully understood why POCA had an increased uptake compared to PBCA. It
was found that particles incubated with cells for 21 hours and then re-incubated
with another population of cells had a significantly increased uptake compared
to the reference particles. There are mechanisms there that if understood could
be important for manufacturing particles with properties that are ideal for maxi-
mum cellular uptake. It is also important to understand and quantify the escape
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from lysosomes that was indicated in this thesis. A specific suggestion would
be do a thorough colocalization study with the NPs and early endosomes, late
endosomes and lysosomes. It would be essential and also novel knowledge if this
process was understood and if lysosomal escape could be demonstrated.
It is also suggested that continued work is done to utilize FLIM and NR668
for potentially new applications. The effect of various parameters was not fully
understood. However, it was found that FLIM is far more sensitive than spectral
measurements and that in combination with NR668, it can be used to evaluate
intracellular properties. One specific suggestion is that co-localization with or-
ganelles such as lysosomes and endosomes is combined with FLIM measurements
both on endocytosed NPs and on free NR668. It is hypothesized that a clear
footprint of lysosomal pH and free NR668 can be seen in FLIM images.
Chapter 6
Conclusion
In this thesis the cellular uptake and degradation of PBCA and POCA parti-
cles has been evaluated. CLSM and FC was used in combination with various
organelle staining and endocytosis inhibitors to assess the cellular uptake. The
degradation was measured using FLIM, emission specter analysis and cell lysis
with Triton. This led to the following conclusions:
• The PBCA particles were endocytosed primarily through clathrin-mediated
endocytosis. The uptake was relatively low compared to POCA after 3
hours, but highly dependent on cell confluency and maturation, with a 4
fold higher uptake after 5 days of incubation compared to 3 days. It is
therefore questionable how relevant the measured uptake is to evaluated
in vivo properties of the particles. The PBCA particles were found to be
degraded mainly within the first 24-48 hours after incubation, this is a
favorable rate for drug delivery.
• The POCA particles were endocytosed 3-fold more than the PBCA particles
after 3 hours, with the same dependency on confluency and maturation.
The particles were not found to degrade readily within the first week of
incubation, making them too stable for most drug delivery. This rate might
be better suited for imaging applications.
• Both colocalization with lysosomes and the rate of degradation suggest that
these particles are able to escape the lysosomes and degrade in cytosol. This
process should be further analyzed and quantified.
• It was found that FLIM and spectral analysis can both be used to evaluate
intracellular degradation. FLIM is more sensitive and holds potentially a lot
91
92 CHAPTER 6. CONCLUSION
more information than spectral analysis, but is also far more complicated
and the results have a higher standard deviation and are harder to interpret.
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Appendix A
Fluorescence intensity
The fluorescence intensity from POCA NP (Targ 76) and PACA NP (Targ 67)
was measured using a plate reader (figure A.1 ). The work was done by Eva von
Haartman and Andreas A˚slund prior to this master thesis.
Figure A.1: Emission intensity of Targ 67 and Targ 76 from 596nm to 748nm.
Excitation wavelength 561nm. Unpublished results from Eva von Haartman.
The normalized fluorescence intensity at wavelength 620 nm is presented in
109
110 APPENDIX A. FLUORESCENCE INTENSITY
table A.1, in order to compare the uptake of PBCA and POCA NP, the fluores-
cence intensity of POCA should therefore be multiplied by 10.52 = 1.923
Table A.1: Normalized fluorescence intensity at 620nm
Particle Normalized intensity
PBCA (Targ 67) 1
POCA (Targ 76) 0.52
Appendix B
Endocytosis inhibition
Inhibition of endocytosis was done twice, and the bar plots in figure 4.10 comes
from adding those two. These two experiments were performed at different cell
density resulting from different time of cultivation before inhibitors and cells
were added. The uptake of PBCA is seen in figure B.1 with the experiment of
low density in A and high density in B. The same for POCA is seen in figure B.2.
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Figure B.1: Histograms from FC showing the uptake of PBCA suppressed by
inhibitors in the experiment of low density (A), and high density of B.
113
Figure B.2: Histograms from FC showing the uptake of POCA suppressed by
inhibitors in the experiment of low density (A), and high density of B.
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Appendix C
Fluorescence lifetimes
Table C.1 shows the exact lifetimes measured on the various time points after
incubation.
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Table C.1: Lifetimes of NR668 inside POCA and PBCA particles inside PC3
cells. Average and standard deviation based on 6 images.
PBCA
Time τ1(ns) τ2(ns)
0h 0.72 (± 0.03) 3.15 (± 0.12)
5h 0.82 (± 0.08) 3.13 (± 0.11)
24-48h 1.05 (± 0.17) 3.44 (± 0.12)
6-7 days 1.22 (± 0.10) 3.58 (± 0.12)
POCA
Time τ1(ns) τ2(ns)
0h 1.03 (± 0.36) 3.69 (± 0.20)
5h 1.05 (± 0.09) 3.64 (± 0.13)
24-48h 1.03 (± 0.09) 3.52 (± 0.13)
6-7 days 1.19 (± 0.29) 3.62 (± 0.19)
NR668
Time τ1(ns) τ2(ns)
0h -* -*
5h 0.93 (± 0.21) 3.45(± 0.10)
24-48h 0.91 (± 0.11) 3.31 (± 0.12)
6-7 days 0.79 (± 0.17) 3.10 (± 0.14)
*Free NR668 could not be imaged at 0h because it is essentially quenched in
water and does not attach to the sample chamber.
